```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2829 Reported in House (RH)]

                                                 Union Calendar No. 209
109th CONGRESS
  2d Session
                                H. R. 2829

               [Report No. 109-315, Parts I, II, and III]

     To reauthorize the Office of National Drug Control Policy Act.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              June 9, 2005

 Mr. Souder (for himself and Mr. Tom Davis of Virginia) introduced the 
   following bill; which was referred to the Committee on Government 
Reform, and in addition to the Committees on the Judiciary, Energy and 
 Commerce, and Select Intelligence (Permanent Select), for a period to 
      be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the 
                          committee concerned

                           November 18, 2005

   Reported from the Committee on Government Reform with an amendment
 [Strike out all after the enacting clause and insert the part printed 
                           in boldface roman]

                           November 18, 2005

 Referral to the Committees on the Judiciary, Energy and Commerce, and 
 the Permanent Select Committee on Intelligence extended for a period 
                ending not later than December 17, 2005

                           November 18, 2005

 Referred to the Committee on Education and the Workforce for a period 
  ending not later than December 17, 2005, for consideration of such 
provisions of the bill and amendment as fall within the jurisdiction of 
             that committee pursuant to clause (e), rule X

                           December 17, 2005

 Referral to the Committees on the Judiciary, Energy and Commerce, the 
   Permanent Select Committee on Intelligence, and the Committee on 
Education and the Workforce extended for a period ending not later than 
                           December 31, 2005

                           December 31, 2005

 Referral to the Committees on the Judiciary, Energy and Commerce, the 
   Permanent Select Committee on Intelligence, and the Committee on 
Education and the Workforce extended for a period ending not later than 
                            February 3, 2006

                            February 3, 2006

 Referral to the Committees on the Judiciary, Energy and Commerce, the 
   Permanent Select Committee on Intelligence, and the Committee on 
Education and the Workforce extended for a period ending not later than 
                             March 3, 2006

                             March 3, 2006

  Reported from the Committee on Energy and Commerce with an amendment
            [Omit the part struck through in boldface roman]

                             March 3, 2006

     Reported from the Committee on the Judiciary with an amendment
 [Strike out all after the enacting clause and insert the part printed 
                               in italic]

                             March 3, 2006

  The Permanent Select Committee on Intelligence and the Committee on 
 Education and the Workforce discharged; committed to the Committee of 
  the Whole House on the State of the Union and ordered to be printed
[For text of introduced bill, see copy of bill as introduced on June 9, 
                                 2005]

_______________________________________________________________________

                                 A BILL

 
     To reauthorize the Office of National Drug Control Policy Act.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. TABLE OF CONTENTS.

    (a) Table of Contents.--The table of contents for this Act is as 
follows:

Sec. 1. Table of contents.
   TITLE I--REAUTHORIZATION OF OFFICE OF NATIONAL DRUG CONTROL POLICY

Sec. 101. Short title.
Sec. 102. Amendment of Office of National Drug Control Policy 
                            Reauthorization Act of 1998.
Sec. 103. Repeal of termination provision.
Sec. 104. Amendments to definitions.
Sec. 105. Amendments relating to establishment of Office of National 
                            Drug Control Policy and designation of 
                            officers.
Sec. 106. Amendments relating to appointment and duties of Director and 
                            Deputy Director.
Sec. 107. Amendments relating to coordination with other agencies.
Sec. 108. Development, submission, implementation, and assessment of 
                            National Drug Control Strategy.
Sec. 109. High Intensity Drug Trafficking Areas Program.
Sec. 110. Funding for certain High Intensity Drug Trafficking Areas.
Sec. 111. Amendments relating to Counter-Drug Technology Assessment 
                            Center.
Sec. 112. National youth antidrug media campaign.
Sec. 113. Drug interdiction.
Sec. 114. Authorization of appropriations.
Sec. 115. Technical amendments and repeal.
Sec. 116. Requirement for disclosure of Federal sponsorship of all 
                            Federal advertising or other communication 
                            materials.
Sec. 117. Policy relating to syringe exchange programs.
              <DELETED>TITLE II--CLEAN SPORTS ACT OF 2005

<DELETED>Sec. 201. Addition of minimum drug testing standards to Office 
                            of National Drug Control Policy Act.

 </DELETED>TITLE I--REAUTHORIZATION OF OFFICE OF NATIONAL DRUG CONTROL 
                                 POLICY

SEC. 101. SHORT TITLE.

    This title may be cited as the ``Office of National Drug Control 
Policy Reauthorization Act of 2005''.

SEC. 102. AMENDMENT OF OFFICE OF NATIONAL DRUG CONTROL POLICY 
              REAUTHORIZATION ACT OF 1998.

    Except as otherwise expressly provided, whenever in this title an 
amendment or repeal is expressed in terms of an amendment to, or repeal 
of, a section or other provision, the reference shall be considered to 
be made to a section or other provision of the Office of National Drug 
Control Policy Reauthorization Act of 1998 (Public Law 105-277; 21 
U.S.C. 1701 et seq.).

SEC. 103. REPEAL OF TERMINATION PROVISION.

    Section 715 (21 U.S.C. 1712) is repealed, and the law shall read as 
if such section was never in effect.

SEC. 104. AMENDMENTS TO DEFINITIONS.

    (a) Amendments to Definitions.--Section 702 (21 U.S.C. 1701) is 
amended--
            (1) in paragraph (1)--
                    (A) by striking ``and'' at the end of subparagraph 
                (F);
                    (B) by striking the period at the end of 
                subparagraph (G) and inserting ``, including the 
                testing of employees;''; and
                    (C) by adding at the end the following:
                    ``(H) interventions for drug abuse and dependence; 
                and
                    ``(I) international drug control coordination and 
                cooperation with respect to activities described in 
                this paragraph.'';
            (2) in paragraph (6), by adding before the period at the 
        end: ``, including any activities involving supply reduction, 
        demand reduction, or State and local affairs'';
            (3) in paragraph (7)--
                    (A) by striking ``Agency'' and inserting 
                ``agency'';
                    (B) by striking ``National Foreign Intelligence 
                Program,'' and inserting ``National Intelligence 
                Program,''; and
                    (C) by inserting a comma before ``or Tactical'';
            (4) in paragraph (9), by striking ``implicates'' and 
        inserting ``indicates'';
            (5) in paragraph (10)--
                    (A) by adding ``National Drug Control Program 
                agencies and'' after ``among'' in subparagraph (B);
                    (B) by striking ``and'' at the end of subparagraph 
                (B);
                    (C) by striking the period at the end of 
                subparagraph (C) and inserting a semicolon; and
                    (D) by adding at the end the following:
                    ``(D) domestic drug law enforcement, including 
                domestic drug interdiction and law enforcement directed 
                at drug users; and
                    ``(E) coordination and enhancement of Federal, 
                State, and local law enforcement initiatives to gather, 
                analyze, and disseminate information and intelligence 
                relating to drug control among domestic law enforcement 
                agencies.'';
            (6) in paragraph (11)--
                    (A) by inserting before the semicolon in 
                subparagraph (A) the following: ``, including--
                            ``(i) law enforcement outside the United 
                        States; and
                            ``(ii) source country programs, including 
                        economic development programs primarily 
                        intended to reduce the production or 
                        trafficking of illicit drugs'';
                    (B) by striking subparagraph (B) and inserting the 
                following:
                    ``(B) facilitating and enhancing the sharing of 
                foreign and domestic information and law enforcement 
                intelligence relating to drug production and 
                trafficking among National Drug Control Program 
                agencies, and between those agencies and foreign law 
                enforcement agencies; and'';
                    (C) by striking ``; and'' at the end of 
                subparagraph (C) and inserting a period; and
                    (D) by striking subparagraph (D); and
            (7) by adding at the end the following:
            ``(12) Appropriate congressional committees.--Except where 
        otherwise provided, the term `appropriate congressional 
        committees' means the Committee on the Judiciary, the Committee 
        on Appropriations, and the Caucus on International Narcotics 
        Control of the Senate and the Committee on Government Reform, 
        the Committee on the Judiciary, and the Committee on 
        Appropriations of the House of Representatives.
            ``(13) Law enforcement.--The term `law enforcement' or 
        `drug law enforcement' means all efforts by a Federal, State, 
        or local government agency to enforce the drug laws of the 
        United States or any State, including investigation, arrest, 
        prosecution, and incarceration or other punishments or 
        penalties.''.
    (b) Conforming Amendments.--Section 703(b)(3) (21 U.S.C. 
1702(b)(3)) is amended--
            (1) in subparagraph (A), by striking ``(G)'' and inserting 
        ``(I)''; and
            (2) in subparagraph (C)--
                    (A) by striking ``through (C)'' and inserting 
                ``through (E)'';
                    (B) by striking ``and subparagraph (D) of section 
                702(11)''; and
                    (C) by adding before the period at the end the 
                following: ``, and sections 707 and 708 of this Act''.

SEC. 105. AMENDMENTS RELATING TO ESTABLISHMENT OF OFFICE OF NATIONAL 
              DRUG CONTROL POLICY AND DESIGNATION OF OFFICERS.

    (a) Responsibilities.--Paragraph (4) of section 703(a) (21 U.S.C. 
1702(a)) is amended to read as follows:
            ``(4) evaluate the effectiveness of the national drug 
        control policy and the National Drug Control Program agencies' 
        programs, by developing and applying specific goals and 
        performance measurements.''.
    (b) Rank of Director.--Section 703(b) (21 U.S.C. 1702(b)) is 
amended in paragraph (1) by adding before the period the following: ``, 
who shall hold the same rank and status as the head of an executive 
department listed in section 101 of title 5, United States Code''.
    (c) Deputy Directors.--Section 703(b) (21 U.S.C. 1702(b)) is 
amended in paragraph (3)--
            (1) by striking ``Office--'' and inserting ``Office the 
        following additional Deputy Directors--''; and
            (2) in subparagraph (B), by striking ``who shall'' and 
        inserting the following: ``who shall have substantial 
        experience and expertise in drug interdiction operations and 
        other supply reduction activities, and who shall serve as the 
        United States Interdiction Coordinator and''.

SEC. 106. AMENDMENTS RELATING TO APPOINTMENT AND DUTIES OF DIRECTOR AND 
              DEPUTY DIRECTOR.

    (a) Designation of Other Officers.--Section 704(a)(3) (21 U.S.C. 
1703(a)(3)) is amended--
            (1) by striking ``permanent employee'' and inserting 
        ``officer or employee''; and
            (2) by striking ``serve as the Director'' and inserting 
        ``serve as the acting Director''.
    (b) Responsibilities of Director.--Section 704(b) (21 U.S.C. 
1703(b)) is amended--
            (1) in paragraph (4), by striking ``Federal departments and 
        agencies engaged in drug enforcement,'' and inserting 
        ``National Drug Control Program agencies,'';
            (2) in paragraph (7), by inserting after ``President'' the 
        following: ``and the appropriate congressional committees'';
            (3) in paragraph (13), by striking ``(beginning in 1999)'';
            (4) in paragraph (14)--
                    (A) by striking ``Appropriations'' and all that 
                follows through ``Senate'' and inserting ``appropriate 
                congressional committees''; and
                    (B) by striking ``and'' after the semicolon at the 
                end;
            (5) in paragraph (15), by striking subparagraph (C) and 
        inserting the following:
                    ``(C) supporting the substance abuse information 
                clearinghouse administered by the Administrator of the 
                Substance Abuse and Mental Health Services 
                Administration and established in section 501(d)(16) of 
                the Public Health Service Act by--
                            ``(i) encouraging all National Drug Control 
                        Program agencies to provide all appropriate and 
                        relevant information; and
                            ``(ii) supporting the dissemination of 
                        information to all interested entities;''; and
            (6) by inserting at the end the following:
            ``(16) shall coordinate with the private sector to promote 
        private research and development of medications to treat 
        addiction;
            ``(17) shall seek the support and commitment of State and 
        local officials in the formulation and implementation of the 
        National Drug Control Strategy;
            ``(18) shall monitor and evaluate the allocation of 
        resources among Federal law enforcement agencies in response to 
        significant local and regional drug trafficking and production 
        threats; and
            ``(19) shall submit an annual report to Congress detailing 
        how the Office of National Drug Control Policy has consulted 
        with and assisted State and local governments with respect to 
        the formulation and implementation of the National Drug Control 
        Strategy and other relevant issues.''.
    (c) Submission of Drug Control Budget Requests.--Section 704(c)(1) 
is amended by adding at the end the following:
                    ``(C) Content of drug control budget requests.--A 
                drug control budget request submitted by a department, 
                agency, or program under this paragraph shall include 
                all requests for funds for any drug control activity 
                undertaken by that department, agency, or program, 
                including demand reduction, supply reduction, and State 
                and local affairs, including any drug law enforcement 
                activities. If an activity has both drug control and 
                nondrug control purposes or applications, the 
                department, agency, or program shall estimate by a 
                documented calculation the total funds requested for 
                that activity that would be used for drug control, and 
                shall set forth in its request the basis and method for 
                making the estimate.''.
    (d) National Drug Control Budget Proposal.--Section 704(c)(2) is 
amended in subparagraph (A) by inserting before the semicolon: ``and to 
inform Congress and the public about the total amount proposed to be 
spent on all supply reduction, demand reduction, State and local 
affairs, including any drug law enforcement, and other drug control 
activities by the Federal Government, which shall conform to the 
content requirements set forth in subparagraph (C) of paragraph (1) of 
this subsection''.
    (e) Review and Certification of National Drug Control Program 
Budget.--Section 704(c)(3) (21 U.S.C. 1703(c)(3)) is amended--
            (1) by redesignating subparagraphs (C) and (D) as 
        subparagraphs (D) and (E), respectively;
            (2) by inserting after subparagraph (B) the following new 
        subparagraph:
                    ``(C) Specific requests.--The Director shall not 
                confirm the adequacy of any budget request that--
                            ``(i) requests funding for Federal law 
                        enforcement activities that do not adequately 
                        compensate for transfers of drug enforcement 
                        resources and personnel to law enforcement and 
                        investigation activities not related to drug 
                        enforcement as determined by the Director;
                            ``(ii) requests funding for law enforcement 
                        activities on the borders of the United States 
                        that do not adequately direct resources to drug 
                        interdiction and enforcement as determined by 
                        the Director;
                            ``(iii) requests funding for drug treatment 
                        activities that do not provide adequate result 
                        and accountability measures as determined by 
                        the Director;
                            ``(iv) requests funding for any activities 
                        of the Safe and Drug Free Schools Program that 
                        do not include a clear antidrug message or 
                        purpose intended to reduce drug use;
                            ``(v) requests funding to enforce section 
                        484(r)(1) of the Higher Education Act of 1965 
                        (20 U.S.C. 1091(r)(1)) with respect to 
                        convictions for drug-related offenses not 
                        occurring during a period of enrollment for 
                        which the student was receiving any Federal 
                        grant, loan, or work assistance;
                            ``(vi) requests funding for drug treatment 
                        activities that do not adequately support and 
                        enhance Federal drug treatment programs and 
                        capacity, as determined by the Director;
                            ``(vii) requests funding for fiscal year 
                        2007 for activities of the Department of 
                        Education, unless it is accompanied by a report 
                        setting forth a plan for providing expedited 
                        consideration of student loan applications for 
                        all individuals who submitted an application 
                        for any Federal grant, loan, or work assistance 
                        that was rejected or denied pursuant to 
                        484(r)(1) of the Higher Education Act of 1965 
                        (20 U.S.C. 1091(r)(1)) by reason of a 
                        conviction for a drug-related offense not 
                        occurring during a period of enrollment for 
                        which the individual was receiving any Federal 
                        grant, loan, or work assistance;
                            ``(viii) requests funding for the 
                        operations and management of the Department of 
                        Homeland Security that does not include a 
                        specific request for funds for the Office of 
                        Counternarcotics Enforcement to carry out its 
                        responsibilities under section 878 of the 
                        Homeland Security Act of 2002 (6 U.S.C. 
                        458).'';
            (3) in subparagraph (D)(iii), as so redesignated, by 
        inserting ``and the appropriate congressional committees'' 
        after ``House of Representatives''; and
            (4) in subparagraph (E)(ii)(II)(bb), as so redesignated, by 
        inserting ``and the appropriate congressional committees'' 
        after ``House of Representatives''.
    (f) Reprogramming and Transfer Requests.--Section 704(c)(4)(A) (21 
U.S.C. 1703(c)(4)(A)) is amended by striking ``$5,000,000'' and 
inserting ``$1,000,000''.
    (g) Powers of Director.--Section 704(d) (21 U.S.C. 1703(d)) is 
amended--
            (1) in paragraph (8)(D), by striking ``have been authorized 
        by Congress;'' and inserting ``authorized by law;'';
            (2) in paragraph (9)--
                    (A) by inserting ``notwithstanding any other 
                provision of law,'' after ``(9)''; and
                    (B) by striking ``Strategy; and'' and inserting 
                ``Strategy and notify the appropriate congressional 
                committees of any fund control notice issued;'';
            (3) in paragraph (10), by striking ``(22 U.S.C. 2291j).'' 
        and inserting ``(22 U.S.C. 2291j) and section 706 of the 
        Foreign Relations Authorization Act, Fiscal Year 2003 (22 
        U.S.C. 2291j-1); and''; and
            (4) by adding at the end the following new paragraph:
            ``(11) not later than August 1 of each year, submit to the 
        President a report, and transmit copies of the report to the 
        Secretary of State and the appropriate congressional 
        committees, that--
                    ``(A) provides the Director's assessment of which 
                countries are major drug transit countries or major 
                illicit drug producing countries as defined in section 
                481(e) of the Foreign Assistance Act of 1961 (22 U.S.C. 
                2291(e));
                    ``(B) provides the Director's assessment of whether 
                each country identified under subparagraph (A) has 
                cooperated fully with the United States or has taken 
                adequate steps on its own to achieve full compliance 
                with the goals and objectives established by the United 
                Nations Convention Against Illicit Traffic in Narcotic 
                Drugs and Psychotropic Substances and otherwise has 
                assisted in reducing the supply of illicit drugs to the 
                United States; and
                    ``(C) provides the Director's assessment of whether 
                application of procedures set forth in section 490 of 
                the Foreign Assistance Act of 1961 (22 U.S.C. 2291j), 
                as provided in section 706 of the Foreign Relations 
                Authorization Act, Fiscal Year 2003 (22 U.S.C. 2291j-
                1), is warranted with respect to countries the Director 
                assesses have not cooperated fully.''.
    (g) Fund Control Notices.--Section 704(f) (21 U.S.C. 1703(f)) is 
amended by adding at the end the following:
            ``(4) Congressional notice.--A copy of each fund control 
        notice shall be transmitted to the appropriate congressional 
        committees.
            ``(5) Restrictions.--The Director shall not issue a fund 
        control notice to direct that all or part of an amount 
        appropriated to the National Drug Control Program agency 
        account be obligated, modified, or altered in any manner 
        contrary, in whole or in part, to a specific appropriation or 
        statute.''.
    (h) Technical Amendments.--Section 704 (21 U.S.C. 1703) is 
amended--
            (1) in subsection (g)--
                    (A) by striking ``National Foreign Intelligence 
                Program'' and inserting ``National Intelligence 
                Program''; and
                    (B) by inserting a comma before ``and Tactical''; 
                and
            (2) in subsection (h), by striking ``Director of Central 
        Intelligence'' and inserting ``Director of National 
        Intelligence or the Director of the Central Intelligence 
        Agency''.
    (i) Requirement for South American Heroin Strategy.--
            (1) In general.--Not later than 90 days after the date of 
        the enactment of this Act, the Director of National Drug 
        Control Policy shall submit to the Congress a comprehensive 
        strategy that addresses the increased threat from South 
        American heroin, and in particular Colombian heroin and the 
        emerging threat from opium poppy grown in Peru and often 
        intended for transit to Columbia for processing into heroin.
            (2) Contents.--The strategy shall include--
                    (A) opium eradication efforts to eliminate the 
                problem at the source to prevent heroin from entering 
                the stream of commerce;
                    (B) interdiction and precursor chemical controls;
                    (C) demand reduction and treatment;
                    (D) alternative development programs, including 
                direct assistance to regional governments to demobilize 
                and provide alternative livelihoods to former members 
                of insurgent or other groups engaged in heroin, coca, 
                or other illicit drug production or trafficking;
                    (E) efforts to inform and involve local citizens in 
                the programs described in subparagraphs (A) through 
                (D), such as through leaflets advertising rewards for 
                information;
                    (F) provisions that ensure the maintenance at 
                current levels of efforts to eradicate coca in 
                Colombia; and
                    (G) assessment of the specific level of funding and 
                resources necessary to simultaneously address the 
                threat from South American heroin and the threat from 
                Colombian and Peruvian coca.
            (3) Treatment of classified or law enforcement sensitive 
        information.--Any content of the strategy that involves 
        information classified under criteria established by an 
        Executive order, or whose public disclosure, as determined by 
        the Director or the head of any relevant Federal agency, would 
        be detrimental to the law enforcement or national security 
        activities of any Federal, foreign, or international agency, 
        shall be presented to Congress separately from the rest of the 
        strategy.
    (j) Requirement for Afghan Heroin Strategy.--
            (1) In general.--Not later than 90 days after the date of 
        the enactment of this Act, the Director of the Office of 
        National Drug Control Policy shall submit to the Congress a 
        comprehensive strategy that addresses the increased threat from 
        Afghan heroin.
            (2) Contents.--The strategy shall include--
                    (A) opium crop eradication efforts to eliminate the 
                problem at the source to prevent heroin from entering 
                the stream of commerce;
                    (B) destruction or other direct elimination of 
                stockpiles of heroin and raw opium, and heroin 
                production and storage facilities;
                    (C) interdiction and precursor chemical controls;
                    (D) demand reduction and treatment;
                    (E) alternative development programs;
                    (F) measures to improve cooperation and 
                coordination between Federal Government agencies, and 
                between such agencies, agencies of foreign governments, 
                and international organizations with responsibility for 
                the prevention of heroin production in, or trafficking 
                out of, Afghanistan; and
                    (G) an assessment of the specific level of funding 
                and resources necessary significantly to reduce the 
                production and trafficking of heroin.
            (3) Treatment of classified or law enforcement sensitive 
        information.--Any content of the strategy that involves 
        information classified under criteria established by an 
        Executive order, or whose public disclosure, as determined by 
        the Director or the head of any relevant Federal agency, would 
        be detrimental to the law enforcement or national security 
        activities of any Federal, foreign, or international agency, 
        shall be presented to Congress separately from the rest of the 
        strategy.
    (k) Requirement for General Counterdrug Intelligence Plan.--
            (1) In general.--Not later than 120 days after the date of 
        enactment of this Act, and not later than every two years 
        thereafter, the Director of the Office of National Drug Control 
        Policy, with the concurrence of the Director of National 
        Intelligence, shall submit to the appropriate congressional 
        committees, a general counterdrug intelligence plan to improve 
        coordination, and eliminate unnecessary duplication, among the 
        counterdrug intelligence centers and information sharing 
        systems, and counterdrug activities of the Federal Government, 
        including the centers, systems, and activities of the following 
        departments and agencies:
                    (A) The Department of Defense, including the 
                Defense Intelligence Agency, and the joint interagency 
                task forces.
                    (B) The Department of the Treasury, including the 
                Financial Crimes Enforcement Network (FinCEN).
                    (C) The Central Intelligence Agency.
                    (D) The National Security Agency.
                    (E) The Department of Homeland Security, including 
                the United States Coast Guard, the bureau of Customs 
                and Border Protection, and the bureau of Immigration 
                and Customs Enforcement.
                    (F) The Department of Justice, including the 
                National Drug Intelligence Center (NDIC); the Drug 
                Enforcement Administration, including the El Paso 
                Intelligence Center (EPIC); the Federal Bureau of 
                Investigation; the Organized Crime Drug Enforcement 
                Task Force; and the Regional Information Sharing 
                System.
                    (G) The Office of National Drug Control Policy, 
                including the High Intensity Drug Trafficking Areas 
                Program.
                    (H) The Counterdrug Intelligence Executive 
                Secretariat.
            (2) Purpose.--The purpose of the plan under paragraph (1) 
        is to maximize the effectiveness of the centers and activities 
        referred to in that paragraph in achieving the objectives of 
        the National Drug Control Strategy promulgated under 21 U.S.C. 
        1705. In order to maximize such effectiveness, the plan shall--
                    (A) articulate clear and specific mission 
                statements (including purpose and scope of activity) 
                for each counterdrug intelligence center, system, and 
                activity, including the manner in which responsibility 
                for counterdrug intelligence activities will be 
                allocated among the counterdrug intelligence centers 
                and systems;
                    (B) specify each government agency (whether 
                Federal, State, or local) that participates in each 
                such center, system, and activity, including a 
                description of the extent and nature of that 
                participation;
                    (C) specify the relationship between such centers, 
                systems, and activities;
                    (D) specify the means by which proper oversight of 
                such centers, systems, and activities will be assured;
                    (E) specify the means by which counterdrug 
                intelligence and information will be forwarded 
                effectively to all levels of officials responsible for 
                United States counterdrug policy; and
                    (F) specify mechanisms to ensure that State and 
                local law enforcement agencies are apprised of 
                counterdrug intelligence and information acquired by 
                Federal law enforcement agencies in a manner which--
                            (i) facilitates effective counterdrug 
                        activities by State and local law enforcement 
                        agencies; and
                            (ii) provides such State and local law 
                        enforcement agencies with the information 
                        relating to the safety of officials involved in 
                        their counterdrug activities.
            (3) Definitions.--As used in this subsection--
                    (A) the term ``center'' refers to any center, 
                office, task force, or other coordinating organization 
                engaged in counterdrug intelligence or information 
                analyzing or sharing activities;
                    (B) the term ``system'' refers to any computerized 
                database or other electronic system used for 
                counterdrug intelligence or information analyzing or 
                sharing activities; and
                    (C) the term ``appropriate congressional 
                committees'' means the following:
                            (i) The Committee on Appropriations, the 
                        Committee on Foreign Relations, the Committee 
                        on the Judiciary, the Committee on Homeland 
                        Security and Governmental Affairs, the Caucus 
                        on International Narcotics Control, and the 
                        Select Committee on Intelligence of the Senate.
                            (ii) The Committee on Appropriations, the 
                        Committee on International Relations, the 
                        Committee on the Judiciary, the Committee on 
                        Government Reform, the Committee on Homeland 
                        Security, and the Permanent Select Committee on 
                        Intelligence of the House of Representatives.
            (4) Limitation.--The general counterdrug intelligence plan 
        shall not--
                    (A) change existing agency authorities or the laws 
                governing interagency relationships, but may include 
                recommendations about changes to such authorities or 
                laws; or
                    (B) include any information about specific methods 
                of obtaining, or sources of, intelligence or 
                information, or any information about specific 
                individuals, cases, investigations, or operations.
            (5) Classified or law enforcement sensitive information.--
        Any content of the general counterdrug intelligence plan that 
        involves information classified under criteria established by 
        an Executive order, or whose public disclosure, as determined 
        by the Director of the Office of National Drug Control Policy, 
        the Director of National Intelligence, or the head of any 
        Federal Government agency whose activities are described in the 
        plan, would be detrimental to the law enforcement or national 
        security activities of any Federal, State, or local agency, 
        shall be presented to Congress separately from the rest of the 
        report.
    (l) Requirement for Southwest Border Counternarcotics Strategy.--
            (1) In general.--Not later than 120 days after the date of 
        enactment of this Act, and every two years thereafter, the 
        Director of National Drug Control Policy shall submit to the 
        Congress a Southwest Border Counternarcotics Strategy.
            (2) Purposes.--The Southwest Border Counternarcotics 
        Strategy shall--
                    (A) set forth the Government's strategy for 
                preventing the illegal trafficking of drugs across the 
                international border between the United States and 
                Mexico, including through ports of entry and between 
                ports of entry on that border;
                    (B) state the specific roles and responsibilities 
                of the relevant National Drug Control Program agencies 
                (as defined in section 702 of the Office of National 
                Drug Control Policy Reauthorization Act of 1998 (21 
                U.S.C. 1701)) for implementing that strategy; and
                    (C) identify the specific resources required to 
                enable the relevant National Drug Control Program 
                agencies to implement that strategy.
            (3) Consultation with other agencies.--The Director shall 
        issue the Southwest Border Counternarcotics Strategy in 
        consultation with the heads of the relevant National Drug 
        Control Program agencies.
            (4) Limitation.--The Southwest Border Counternarcotics 
        Strategy shall not change existing agency authorities or the 
        laws governing interagency relationships, but may include 
        recommendations about changes to such authorities or laws.
            (5) Report to congress.--The Director shall provide a copy 
        of the Southwest Border Counternarcotics Strategy to the 
        appropriate congressional committees (as defined in section 702 
        of the Office of National Drug Control Policy Reauthorization 
        Act of 1998 (21 U.S.C. 1701)), and to the Committee on Armed 
        Services and the Committee on Homeland Security of the House of 
        Representatives, and the Committee on Homeland Security and 
        Governmental Affairs and the Committee on Armed Services of the 
        Senate.
            (6) Treatment of classified or law enforcement sensitive 
        information.--Any content of the Southwest Border 
        Counternarcotics Strategy that involves information classified 
        under criteria established by an Executive order, or whose 
        public disclosure, as determined by the Director or the head of 
        any relevant National Drug Control Program agency, would be 
        detrimental to the law enforcement or national security 
        activities of any Federal, State, or local agency, shall be 
        presented to Congress separately from the rest of the strategy.
    (m) Requirement for Scientific Study of Mycoherbicide in Illicit 
Drug Crop Eradication.--Not later than 90 days after the date of 
enactment of this Act, the Director of the Office of National Drug 
Control Policy shall submit to the Congress a report that includes a 
plan to conduct, on an expedited basis, a scientific study of the use 
of mycoherbicide as a means of illicit drug crop elimination by an 
appropriate Government scientific research entity, including a complete 
and thorough scientific peer review. The study shall include an 
evaluation of the likely human health and environmental impacts of such 
use. The report shall also include a plan to conduct controlled 
scientific testing in a major drug producing nation of mycoherbicide 
naturally existing in the producing nation.

SEC. 107. AMENDMENTS RELATING TO COORDINATION WITH OTHER AGENCIES.

    Section 705 (21 U.S.C. 1704) is amended--
            (1) in subsection (a)(1)(A), by striking ``abuse'';
            (2) in subsection (a)(2)(A), by striking ``Director of 
        Central Intelligence'' and inserting ``Director of National 
        Intelligence'';
            (3) in subsection (a)(2)(B), by striking ``Director of 
        Central Intelligence'' and inserting ``Director of National 
        Intelligence and the Director of the Central Intelligence 
        Agency'';
            (4) by amending paragraph (3) of subsection (a) to read as 
        follows:
            ``(3) Required reports.--
                    ``(A) Secretaries of the interior and 
                agriculture.--The Secretaries of Agriculture and 
                Interior shall, by July 1 of each year, jointly submit 
                to the Director, the appropriate congressional 
                committees, the Committee on Agriculture and the 
                Committee on Resources of the House of Representatives, 
                and the Committee on Agriculture and the Committee on 
                Energy and Natural Resources of the Senate, an 
                assessment of the quantity of illegal drug cultivation 
                and manufacturing in the United States on lands owned 
                or under the jurisdiction of the Federal Government for 
                the preceding year.
                    ``(B) Attorney general.--The Attorney General 
                shall, by July 1 of each year, submit to the Director 
                and the appropriate congressional committees 
                information for the preceding year regarding the number 
                and type of--
                            ``(i) arrests for drug violations;
                            ``(ii) prosecutions for drug violations by 
                        United States Attorneys; and
                            ``(iii) seizures of drugs by each component 
                        of the Department of Justice seizing drugs, as 
                        well as statistical information on the 
                        geographic areas of such seizures.
                    ``(C) Secretary of homeland security.--The 
                Secretary of Homeland Security shall, by July 1 of each 
                year, submit to the Director, the appropriate 
                congressional committees, and the Committee on Homeland 
                Security of the House of Representatives, and the 
                Committee on Homeland Security and Governmental Affairs 
                of the Senate, information for the preceding year 
                regarding--
                            ``(i) the number and type of seizures of 
                        drugs by each component of the Department of 
                        Homeland Security seizing drugs, as well as 
                        statistical information on the geographic areas 
                        of such seizures; and
                            ``(ii) the number of air and maritime 
                        patrol hours undertaken by each component of 
                        that Department primarily dedicated to drug 
                        supply reduction missions.
                    ``(D) Secretary of defense.--The Secretary of 
                Defense shall, by July 1 of each year, submit to the 
                Director, the appropriate congressional committees, the 
                Committee on Armed Services of the House of 
                Representatives, and the Committee on Armed Services of 
                the Senate, information for the preceding year 
                regarding the number of air and maritime patrol hours 
                primarily dedicated to drug supply reduction missions 
                undertaken by each component of the Department of 
                Defense.'';
            (5) in subsection (b)(2)(B), by striking ``Program.'' and 
        inserting ``Strategy.''; and
            (6) in subsection (c), by striking ``in'' and inserting 
        ``on''.

SEC. 108. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, AND ASSESSMENT OF 
              NATIONAL DRUG CONTROL STRATEGY.

    Section 706 (21 U.S.C. 1705) is amended to read as follows:

``SEC. 706. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, AND ASSESSMENT OF 
              NATIONAL DRUG CONTROL STRATEGY.

    ``(a) Timing, Contents, and Process for Development and Submission 
of National Drug Control Strategy.--
            ``(1) In general.--Not later than February 1 of each year, 
        the President shall submit to Congress a National Drug Control 
        Strategy, which shall set forth a comprehensive plan for 
        reducing illicit drug use and the consequences of illicit drug 
        use in the United States by reducing the demand for illegal 
        drugs, limiting the availability of illegal drugs, and 
        conducting law enforcement activities with respect to illegal 
        drugs.
            ``(2) Contents.--
                    ``(A) In general.--The National Drug Control 
                Strategy submitted under paragraph (1) shall include 
                the following:
                            ``(i) Comprehensive, research-based, long-
                        range, and quantifiable goals for reducing 
                        illicit drug use and the consequences of 
                        illicit drug use in the United States.
                            ``(ii) Annual quantifiable objectives for 
                        demand reduction, supply reduction, and law 
                        enforcement activities, specific targets to 
                        accomplish long-range quantifiable reduction in 
                        illicit drug use as determined by the Director, 
                        and specific measurements to evaluate progress 
                        toward the targets and strategic goals.
                            ``(iii) A strategy to reduce the 
                        availability and purity of illegal drugs and 
                        the level of drug-related crime in the United 
                        States.
                            ``(iv) An assessment of Federal 
                        effectiveness in achieving the National Drug 
                        Control Strategy for the previous year, 
                        including a specific evaluation of whether the 
                        objectives and targets for reducing illicit 
                        drug use for the previous year were met and 
                        reasons for the success or failure of the 
                        previous year's Strategy.
                            ``(v) A general review of the status of, 
                        and trends in, international, State, and local 
                        drug control activities to ensure that the 
                        United States pursues well-coordinated and 
                        effective drug control at all levels of 
                        government.
                            ``(vi) A general review of the status of, 
                        and trends in, demand reduction activities by 
                        private sector entities and community-based 
                        organizations, including faith-based 
                        organizations, to determine their effectiveness 
                        and the extent of cooperation, coordination, 
                        and mutual support between such entities and 
                        organizations and Federal, State, and local 
                        government agencies.
                            ``(vii) An assessment of current illicit 
                        drug use (including inhalants and steroids) and 
                        availability, impact of illicit drug use, and 
                        treatment availability, which assessment shall 
                        include--
                                    ``(I) estimates of drug prevalence 
                                and frequency of use as measured by 
                                national, State, and local surveys of 
                                illicit drug use and by other special 
                                studies of nondependent and dependent 
                                illicit drug use;
                                    ``(II) illicit drug use in the 
                                workplace and the productivity lost by 
                                such use; and
                                    ``(III) illicit drug use by 
                                arrestees, probationers, and parolees.
                            ``(viii) An assessment of the reduction of 
                        illicit drug availability, as measured by--
                                    ``(I) the quantities of cocaine, 
                                heroin, marijuana, methamphetamine, 
                                ecstasy, and other drugs available for 
                                consumption in the United States;
                                    ``(II) the amount of marijuana, 
                                cocaine, heroin, methamphetamine, 
                                ecstasy, and precursor chemicals and 
                                other drugs entering the United States;
                                    ``(III) the number of illicit drug 
                                manufacturing laboratories seized and 
                                destroyed and the number of hectares of 
                                marijuana, poppy, and coca cultivated 
                                and destroyed domestically and in other 
                                countries;
                                    ``(IV) the number of metric tons of 
                                marijuana, heroin, cocaine, and 
                                methamphetamine seized and other drugs; 
                                and
                                    ``(V) changes in the price and 
                                purity of heroin, methamphetamine, and 
                                cocaine, changes in the price of 
                                ecstasy, and changes in 
                                tetrahydrocannabinol level of marijuana 
                                and other drugs.
                            ``(ix) An assessment of the reduction of 
                        the consequences of illicit drug use and 
                        availability, which shall include--
                                    ``(I) the burden illicit drug users 
                                place on hospital emergency departments 
                                in the United States, such as the 
                                quantity of illicit drug-related 
                                services provided;
                                    ``(II) the annual national health 
                                care cost of illicit drug use; and
                                    ``(III) the extent of illicit drug-
                                related crime and criminal activity.
                            ``(x) A general review of the status of, 
                        and trends in, of drug treatment in the United 
                        States, by assessing--
                                    ``(I) public and private treatment 
                                utilization; and
                                    ``(II) the number of illicit drug 
                                users the Director estimates meet 
                                diagnostic criteria for treatment.
                            ``(xi) A review of the research agenda of 
                        the Counterdrug Technology Assessment Center to 
                        reduce the availability and abuse of drugs.
                            ``(xii) A summary of the efforts made by 
                        Federal agencies to coordinate with private 
                        sector entities to conduct private research and 
                        development of medications to treat addiction 
                        by--
                                    ``(I) screening chemicals for 
                                potential therapeutic value;
                                    ``(II) developing promising 
                                compounds;
                                    ``(III) conducting clinical trials;
                                    ``(IV) seeking, where appropriate, 
                                Food and Drug Administration approval 
                                for drugs to treat addiction;
                                    ``(V) marketing, where appropriate, 
                                the drug for the treatment of 
                                addiction;
                                    ``(VI) urging physicians, where 
                                appropriate, to use the drug in the 
                                treatment of addiction; and
                                    ``(VII) encouraging, where 
                                appropriate, insurance companies to 
                                reimburse the cost of the drug for the 
                                treatment of addiction.
                            ``(xiii) Such additional statistical data 
                        and information as the Director considers 
                        appropriate to demonstrate and assess trends 
                        relating to illicit drug use, the effects and 
                        consequences of illicit drug use, supply 
                        reduction, demand reduction, drug-related law 
                        enforcement, and the implementation of the 
                        National Drug Control Strategy.
                            ``(xiv) A supplement reviewing the 
                        activities of each individual National Drug 
                        Control Program agency during the previous year 
                        with respect to the National Drug Control 
                        Strategy and the Director's assessment of the 
                        progress of each National Drug Control Program 
                        agency in meeting its responsibilities under 
                        the National Drug Control Strategy.
                    ``(B) Classified information.--Any contents of the 
                National Drug Control Strategy that involve information 
                properly classified under criteria established by an 
                Executive order shall be presented to Congress 
                separately from the rest of the National Drug Control 
                Strategy.
                    ``(C) Selection of data and information.--In 
                selecting data and information for inclusion under 
                subparagraph (A), the Director shall ensure--
                            ``(i) the inclusion of data and information 
                        that will permit analysis of current trends 
                        against previously compiled data and 
                        information where the Director believes such 
                        analysis enhances long-term assessment of the 
                        National Drug Control Strategy; and
                            ``(ii) the inclusion of data and 
                        information to permit a standardized and 
                        uniform assessment of the effectiveness of drug 
                        treatment programs in the United States.
            ``(3) Process for development and submission.--
                    ``(A) Consultation.--In developing and effectively 
                implementing the National Drug Control Strategy, the 
                Director--
                            ``(i) shall consult with--
                                    ``(I) the heads of the National 
                                Drug Control Program agencies;
                                    ``(II) Congress;
                                    ``(III) State and local officials;
                                    ``(IV) private citizens and 
                                organizations, including community- and 
                                faith-based organizations, with 
                                experience and expertise in demand 
                                reduction;
                                    ``(V) private citizens and 
                                organizations with experience and 
                                expertise in supply reduction;
                                    ``(VI) private citizens and 
                                organizations with experience and 
                                expertise in law enforcement; and
                                    ``(VII) appropriate representatives 
                                of foreign governments;
                            ``(ii) with the concurrence of the Attorney 
                        General, may require the El Paso Intelligence 
                        Center to undertake specific tasks or projects 
                        to implement the National Drug Control 
                        Strategy;
                            ``(iii) with the concurrence of the 
                        Director of National Intelligence and the 
                        Attorney General, may request that the National 
                        Drug Intelligence Center undertake specific 
                        tasks or projects to implement the National 
                        Drug Control Strategy; and
                            ``(iv) may make recommendations to the 
                        Secretary of Health and Human Services on 
                        research that supports or advances the National 
                        Drug Control Strategy.
                    ``(B) Commitment to support strategy.--In 
                satisfying the requirements of subparagraph (A)(i), the 
                Director shall ensure, to the maximum extent possible, 
                that State and local officials and relevant private 
                organizations commit to support and take steps to 
                achieve the goals and objectives of the National Drug 
                Control Strategy.
                    ``(C) Recommendations.--Recommendations under 
                subparagraph (A)(iv) may include recommendations of 
                research to be performed at the National Institutes of 
                Health, including the National Institute on Drug Abuse, 
                or any other appropriate agency within the Department 
                of Health and Human Services.
                    ``(D) Inclusion in strategy.--The National Drug 
                Control Strategy under this subsection shall include a 
                list of each entity consulted under subparagraph 
                (A)(i).
            ``(4) Submission of revised strategy.--The President may 
        submit to Congress a revised National Drug Control Strategy 
        that meets the requirements of this section--
                    ``(A) at any time, upon a determination by the 
                President, in consultation with the Director, that the 
                National Drug Control Strategy in effect is not 
                sufficiently effective; or
                    ``(B) if a new President or Director takes office.
    ``(b) Performance Measurement System.--Not later than February 1 of 
each year, the Director shall submit to Congress, as part of the 
National Drug Control Strategy, a description of a national drug 
control performance measurement system that--
            ``(1) develops 2-year and 5-year performance measures and 
        targets for each National Drug Control Strategy goal and 
        objective established for reducing drug use, drug availability, 
        and the consequences of drug use;
            ``(2) describes the sources of information and data that 
        will be used for each performance measure incorporated into the 
        performance measurement system;
            ``(3) identifies major programs and activities of the 
        National Drug Control Program agencies that support the goals 
        and annual objectives of the National Drug Control Strategy;
            ``(4) evaluates the contribution of demand reduction and 
        supply reduction activities implemented by each National Drug 
        Control Program agency in support of the National Drug Control 
        Strategy;
            ``(5) monitors consistency of drug-related goals and 
        objectives among the National Drug Control Program agencies and 
        ensures that each agency's goals, objectives, and budgets 
        support and are fully consistent with the National Drug Control 
        Strategy; and
            ``(6) coordinates the development and implementation of 
        national drug control data collection and reporting systems to 
        support policy formulation and performance measurement, 
        including an assessment of--
                    ``(A) the quality of current drug use measurement 
                instruments and techniques to measure supply reduction 
                and demand reduction activities;
                    ``(B) the adequacy of the coverage of existing 
                national drug use measurement instruments and 
                techniques to measure the illicit drug user population, 
                and groups that are at risk for illicit drug use; and
                    ``(C) the adequacy of the coverage of existing 
                national treatment outcome monitoring systems to 
                measure the effectiveness of drug abuse treatment in 
                reducing illicit drug use and criminal behavior during 
                and after the completion of substance abuse treatment; 
                and
            ``(7) identifies the actions the Director shall take to 
        correct any inadequacies, deficiencies, or limitations 
        identified in the assessment described in paragraph (6).
    ``(c) Modifications.--A description of any modifications made 
during the preceding year to the national drug performance measurement 
system described in subsection (b) shall be included in each report 
submitted under subsection (a).''.

SEC. 109. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.

    Section 707 (21 U.S.C. 1706) is amended to read as follows:

``SEC. 707. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.

    ``(a) Establishment.--
            ``(1) In general.--There is established in the Office a 
        program to be known as the High Intensity Drug Trafficking 
        Areas Program (in this section referred to as the `Program').
            ``(2) Purpose.--The purpose of the Program is to reduce 
        drug trafficking and drug production in the United States by--
                    ``(A) facilitating cooperation among Federal, 
                State, and local law enforcement agencies to share 
                information and implement coordinated enforcement 
                activities;
                    ``(B) enhancing intelligence sharing among Federal, 
                State, and local law enforcement agencies;
                    ``(C) providing reliable intelligence to law 
                enforcement agencies needed to design effective 
                enforcement strategies and operations; and
                    ``(D) supporting coordinated law enforcement 
                strategies which maximize use of available resources to 
                reduce the supply of illegal drugs in designated areas 
                and in the United States as a whole.
    ``(b) Designation.--The Director, upon consultation with the 
Attorney General, the Secretary of the Treasury, the Secretary of 
Homeland Security, heads of the National Drug Control Program agencies, 
and the Governor of each applicable State, may designate any specified 
area of the United States as a high intensity drug trafficking area. 
After making such a designation and in order to provide Federal 
assistance to the area so designated, the Director may--
            ``(1) obligate such sums as are appropriated for the 
        Program;
            ``(2) direct the temporary reassignment of Federal 
        personnel to such area, subject to the approval of the head of 
        the department or agency that employs such personnel;
            ``(3) take any other action authorized under section 704 to 
        provide increased Federal assistance to those areas; and
            ``(4) coordinate activities under this section 
        (specifically administrative, recordkeeping, and funds 
        management activities) with State and local officials.
    ``(c) Petitions for Designation.--The Director shall establish 
regulations under which a coalition of interested law enforcement 
agencies from an area may petition for designation as a high intensity 
drug trafficking area. Such regulations shall provide for a regular 
review by the Director of the petition, including a recommendation 
regarding the merit of the petition to the Director by a panel of 
qualified, independent experts.
    ``(d) Factors for Consideration.--In considering whether to 
designate an area under this section as a high intensity drug 
trafficking area, the Director shall consider, in addition to such 
other criteria as the Director considers to be appropriate, the extent 
to which--
            ``(1) the area is a significant center of illegal drug 
        production, manufacturing, importation, or distribution;
            ``(2) State and local law enforcement agencies have 
        committed resources to respond to the drug trafficking problem 
        in the area, thereby indicating a determination to respond 
        aggressively to the problem;
            ``(3) drug-related activities in the area are having a 
        significant harmful impact in the area, and in other areas of 
        the country; and
            ``(4) a significant increase in allocation of Federal 
        resources is necessary to respond adequately to drug-related 
        activities in the area.
    ``(e) Organization of High Intensity Drug Trafficking Areas.--
            ``(1) Executive board and officers.--To be eligible for 
        funds appropriated under this section, each high intensity drug 
        trafficking area shall be governed by an Executive Board. The 
        Executive Board shall designate a chairman, vice chairman, and 
        any other officers to the Executive Board that it determines 
        are necessary.
            ``(2) Responsibilities.--The Executive Board of a high 
        intensity drug trafficking area shall be responsible for--
                    ``(A) providing direction and oversight in 
                establishing and achieving the goals of the high 
                intensity drug trafficking area;
                    ``(B) managing the funds of the high intensity drug 
                trafficking area;
                    ``(C) reviewing and approving all funding proposals 
                consistent with the overall objective of the high 
                intensity drug trafficking area; and
                    ``(D) reviewing and approving all reports to the 
                Director on the activities of the high intensity drug 
                trafficking area.
            ``(3) Board representation.--None of the funds appropriated 
        under this section may be expended for any high intensity drug 
        trafficking area, or for a partnership or region of a high 
        intensity drug trafficking area, if that area's, region's or 
        partnership's Executive Board does not apportion an equal 
        number of votes between representatives of participating 
        Federal agencies and representatives of participating State and 
        local agencies. Where it is impractical for a equal number of 
        representatives of Federal agencies and State and local 
        agencies to attend a meeting of an Executive Board in person, 
        the Executive Board may use a system of proxy votes or weighted 
        votes to achieve the voting balance required by this paragraph.
            ``(4) No agency relationship.--The eligibility requirements 
        of this section are intended to ensure the responsible use of 
        Federal funds. Nothing in this section is intended to create an 
        agency relationship between individual high intensity drug 
        trafficking areas and the Federal Government.
    ``(f) Use of Funds.--The Director shall ensure that no Federal 
funds appropriated for the Program are expended for the establishment 
or expansion of drug treatment or drug use prevention programs.
    ``(g) Counterterrorism Activities.--
            ``(1) Assistance authorized.--The Director may authorize 
        use of resources available for the Program to assist Federal, 
        State, and local law enforcement agencies in investigations and 
        activities related to terrorism and prevention of terrorism, 
        especially but not exclusively with respect to such 
        investigations and activities that are also related to drug 
        trafficking.
            ``(2) Limitation.--The Director shall ensure--
                    ``(A) that assistance provided under paragraph (1) 
                remains incidental to the purpose of the Program to 
                reduce drug availability and carry out drug-related law 
                enforcement activities; and
                    ``(B) that significant resources of the Program are 
                not redirected to activities exclusively related to 
                terrorism, except on a temporary basis under 
                extraordinary circumstances, as determined by the 
                Director.
    ``(h) Role of Drug Enforcement Administration.--The Director, in 
consultation with the Attorney General, shall ensure that a 
representative of the Drug Enforcement Administration is included in 
the Intelligence Support Center for each high intensity drug 
trafficking area.
    ``(i) Annual HIDTA Program Budget Submissions.--As part of the 
documentation that supports the President's annual budget request for 
the Office, the Director shall submit to Congress a budget 
justification that includes the following:
            ``(1) The amount requested for each high intensity drug 
        trafficking area with supporting narrative descriptions and 
        rationale for each request.
            ``(2) A detailed justification for each funding request 
        that explains the reasons for the requested funding level, how 
        such funding level was determined based on a current assessment 
        of the drug trafficking threat in each high intensity drug 
        trafficking area, how such funding will ensure that the goals 
        and objectives of each such area will be achieved, and how such 
        funding supports the National Drug Control Strategy.
    ``(j) Emerging Threat Response Fund.--
            ``(1) In general.--The Director may expend up to 10 percent 
        of the amounts appropriated under this section on a 
        discretionary basis, to respond to any emerging drug 
        trafficking threat in an existing high intensity drug 
        trafficking area, or to establish a new high intensity drug 
        trafficking area or expand an existing high intensity drug 
        trafficking area, in accordance with the criteria established 
        under paragraph (2).
            ``(2) Consideration of impact.--In allocating funds under 
        this subsection, the Director shall consider--
                    ``(A) the impact of activities funded on reducing 
                overall drug traffic in the United States, or 
                minimizing the probability that an emerging drug 
                trafficking threat will spread to other areas of the 
                United States; and
                    ``(B) such other criteria as the Director considers 
                appropriate.
    ``(k) Evaluation.--
            ``(1) Initial report.--Not later than 90 days after the 
        date of the enactment of this subsection, the Director shall, 
        after consulting with the Executive Boards of each designated 
        high intensity drug trafficking area, submit a report to 
        Congress that describes, for each designated high intensity 
        drug trafficking area--
                    ``(A) the specific purposes for the high intensity 
                drug trafficking area;
                    ``(B) the specific long-term and short-term goals 
                and objectives for the high intensity drug trafficking 
                area;
                    ``(C) the measurements that will be used to 
                evaluate the performance of the high intensity drug 
                trafficking area in achieving the long-term and short-
                term goals; and
                    ``(D) the reporting requirements needed to evaluate 
                the performance of the high intensity drug trafficking 
                area in achieving the long-term and short-term goals.
            ``(2) Evaluation of hidta program as part of national drug 
        control strategy.--For each designated high intensity drug 
        trafficking area, the Director shall submit, as part of the 
        annual National Drug Control Strategy report, a report that--
                    ``(A) describes--
                            ``(i) the specific purposes for the high 
                        intensity drug trafficking area; and
                            ``(ii) the specific long-term and short-
                        term goals and objectives for the high 
                        intensity drug trafficking area; and
                    ``(B) includes an evaluation of the performance of 
                the high intensity drug trafficking area in 
                accomplishing the specific long-term and short-term 
                goals and objectives identified under paragraph (1)(B).
    ``(l) Assessment of Drug Enforcement Task Forces in High Intensity 
Drug Trafficking Areas.--Not later than 180 days after the date of 
enactment of this subsection, and as part of each subsequent annual 
National Drug Control Strategy report, the Director shall submit to 
Congress a report--
            ``(1) assessing the number and operation of all federally 
        funded drug enforcement task forces within each high intensity 
        drug trafficking area; and
            ``(2) describing--
                    ``(A) each Federal, State, and local drug 
                enforcement task force operating in the high intensity 
                drug trafficking area;
                    ``(B) how such task forces coordinate with each 
                other, with any high intensity drug trafficking area 
                task force, and with investigations receiving funds 
                from the Organized Crime and Drug Enforcement Task 
                Force;
                    ``(C) what steps, if any, each such task force 
                takes to share information regarding drug trafficking 
                and drug production with other federally funded drug 
                enforcement task forces in the high intensity drug 
                trafficking area;
                    ``(D) the role of the high intensity drug 
                trafficking area in coordinating the sharing of such 
                information among task forces;
                    ``(E) the nature and extent of cooperation by each 
                Federal, State, and local participant in ensuring that 
                such information is shared among law enforcement 
                agencies and with the high intensity drug trafficking 
                area;
                    ``(F) the nature and extent to which information 
                sharing and enforcement activities are coordinated with 
                joint terrorism task forces in the high intensity drug 
                trafficking area; and
                    ``(G) any recommendations for measures needed to 
                ensure that task force resources are utilized 
                efficiently and effectively to reduce the availability 
                of illegal drugs in the high intensity drug trafficking 
                areas.
    ``(m) Assessment of Intelligence Sharing in High Intensity Drug 
Trafficking Areas--program.--Not later than 180 days after the date of 
the enactment of this subsection, and as part of each subsequent annual 
National Drug Control Strategy report, the Director shall submit to 
Congress a report--
            ``(1) evaluating existing and planned intelligence systems 
        supported by each high intensity drug trafficking area, or 
        utilized by task forces receiving any funding under the 
        Program, including the extent to which such systems ensure 
        access and availability of intelligence to Federal, State, and 
        local law enforcement agencies within the high intensity drug 
        trafficking area and outside of it;
            ``(2) the extent to which Federal, State, and local law 
        enforcement agencies participating in each high intensity drug 
        trafficking area are sharing intelligence information to assess 
        current drug trafficking threats and design appropriate 
        enforcement strategies; and
            ``(3) the measures needed to improve effective sharing of 
        information and intelligence regarding drug trafficking and 
        drug production among Federal, State, and local law enforcement 
        participating in a high intensity drug trafficking area, and 
        between such agencies and similar agencies outside the high 
        intensity drug trafficking area.
    ``(n) Authorization of Appropriations.--There is authorized to be 
appropriated to the Office of National Drug Control Policy to carry out 
this section--
            ``(1) $280,000,000 for fiscal year 2006;
            ``(2) $290,000,000 for each of fiscal years 2007 and 2008; 
        and
            ``(3) $300,000,000 for each of fiscal years 2009 and 
        2010.''.

SEC. 110. FUNDING FOR CERTAIN HIGH INTENSITY DRUG TRAFFICKING AREAS.

    (a) Short Title.--This section may be cited as the ``Dawson Family 
Community Protection Act''.
    (b) Findings.--Congress finds the following:
            (1) In the early morning hours of October 16, 2002, the 
        home of Carnell and Angela Dawson was firebombed in apparent 
        retaliation for Mrs. Dawson's notification of police about 
        persistent drug distribution activity in their East Baltimore 
        City neighborhood.
            (2) The arson claimed the lives of Mr. and Mrs. Dawson and 
        their 5 young children, aged 9 to 14.
            (3) The horrific murder of the Dawson family is a stark 
        example of domestic narco-terrorism.
            (4) In all phases of counter-narcotics law enforcement--
        from prevention to investigation to prosecution to reentry--the 
        voluntary cooperation of ordinary citizens is a critical 
        component.
            (5) Voluntary cooperation is difficult for law enforcement 
        officials to obtain when citizens feel that cooperation carries 
        the risk of violent retaliation by illegal drug trafficking 
        organizations and their affiliates.
            (6) Public confidence that law enforcement is doing all it 
        can to make communities safe is a prerequisite for voluntary 
        cooperation among people who may be subject to intimidation or 
        reprisal (or both).
            (7) Witness protection programs are insufficient on their 
        own to provide security because many individuals and families 
        who strive every day to make distressed neighborhoods livable 
        for their children, other relatives, and neighbors will resist 
        or refuse offers of relocation by local, State, and Federal 
        prosecutorial agencies and because, moreover, the continued 
        presence of strong individuals and families is critical to 
        preserving and strengthening the social fabric in such 
        communities.
            (8) Where (as in certain sections of Baltimore City) 
        interstate trafficking of illegal drugs has severe ancillary 
        local consequences within areas designated as high intensity 
        drug trafficking areas, it is important that supplementary High 
        Intensity Drug Trafficking Areas Program funds be committed to 
        support initiatives aimed at making the affected communities 
        safe for the residents of those communities and encouraging 
        their cooperation with local, State, and Federal law 
        enforcement efforts to combat illegal drug trafficking.
    (c) Funding for Certain High Intensity Drug Trafficking Areas.--
Section 707 (21 U.S.C. 1706), as amended by section 109, is further 
amended by adding at the end the following new subsection:
    ``(o) Specific Purposes.--
            ``(1) In general.--The Director shall ensure that, of the 
        amounts appropriated for a fiscal year for the Program, at 
        least $5,000,000 is used in high intensity drug trafficking 
        areas with severe neighborhood safety and illegal drug 
        distribution problems.
            ``(2) Required uses.--The funds used under paragraph (1) 
        shall be used--
                    ``(A) to ensure the safety of neighborhoods and the 
                protection of communities, including the prevention of 
                the intimidation of potential witnesses of illegal drug 
                distribution and related activities; and
                    ``(B) to combat illegal drug trafficking through 
                such methods as the Director considers appropriate, 
                such as establishing or operating (or both) a toll-free 
                telephone hotline for use by the public to provide 
                information about illegal drug-related activities.''.

SEC. 111. AMENDMENTS RELATING TO COUNTER-DRUG TECHNOLOGY ASSESSMENT 
              CENTER.

    (a) Chief Scientist.--Section 708(b) (21 U.S.C. 1707(b)) is 
amended--
            (1) in the heading by striking ``Director of Technology.--
        '' and inserting ``Chief Scientist.--''; and
            (2) by striking ``Director of Technology,'' and inserting 
        ``Chief Scientist,''.
    (b) Additional Responsibilities of Director.--Section 708(c) (21 
U.S.C. 1707(c)) is amended to read as follows:
    ``(c) Additional Responsibilities of the Director of National Drug 
Control Policy.--
            ``(1) In general.--The Director, acting through the Chief 
        Scientist shall--
                    ``(A) identify and define the
                short-, medium-, and long-term scientific and 
                technological needs of Federal, State, and local law 
                enforcement agencies relating to drug enforcement, 
                including--
                            ``(i) advanced surveillance, tracking, and 
                        radar imaging;
                            ``(ii) electronic support measures;
                            ``(iii) communications;
                            ``(iv) data fusion, advanced computer 
                        systems, and artificial intelligence; and
                            ``(v) chemical, biological, radiological 
                        (including neutron, electron, and graviton), 
                        and other means of detection;
                    ``(B) identify demand reduction (including drug 
                prevention) basic and applied research needs and 
                initiatives, in consultation with affected National 
                Drug Control Program agencies, including--
                            ``(i) improving treatment through 
                        neuroscientific advances;
                            ``(ii) improving the transfer of biomedical 
                        research to the clinical setting; and
                            ``(iii) in consultation with the National 
                        Institute on Drug Abuse and the Substance Abuse 
                        and Mental Health Services Administration, and 
                        through interagency agreements or grants, 
                        examining addiction and rehabilitation research 
                        and the application of technology to expanding 
                        the effectiveness or availability of drug 
                        treatment;
                    ``(C) make a priority ranking of such needs 
                identified in subparagraphs (A) and (B) according to 
                fiscal and technological feasibility, as part of a 
                National Counterdrug Research and Development Program;
                    ``(D) oversee and coordinate counterdrug technology 
                initiatives with related activities of other Federal 
                civilian and military departments;
                    ``(E) provide support to the development and 
                implementation of the national drug control performance 
                measurement system established under subsection (b) of 
                section 706;
                    ``(F) with the advice and counsel of experts from 
                State and local law enforcement agencies, oversee and 
                coordinate a technology transfer program for the 
                transfer of technology to State and local law 
                enforcement agencies; and
                    ``(G) pursuant to the authority of the Director of 
                National Drug Control Policy under section 704, submit 
                requests to Congress for the reprogramming or transfer 
                of funds appropriated for counterdrug technology 
                research and development.
            ``(2) Priorities in transferring technology.--
                    ``(A) In general.--The Chief Scientist shall give 
                priority, in transferring technology under paragraph 
                (1)(F), based on the following criteria:
                            ``(i) the need of potential recipients for 
                        such technology;
                            ``(ii) the effectiveness of the technology 
                        to enhance current counterdrug activities of 
                        potential recipients; and
                            ``(iii) the ability and willingness of 
                        potential recipients to evaluate transferred 
                        technology.
                    ``(B) Interdiction and border drug law enforcement 
                technologies.--The Chief Scientist shall give priority, 
                in transferring technologies most likely to assist in 
                drug interdiction and border drug law enforcement, to 
                State, local, and tribal law enforcement agencies in 
                southwest border areas and northern border areas with 
                significant traffic in illicit drugs.
            ``(3) Limitation on authority.--The authority granted to 
        the Director under this subsection shall not extend to the 
        direct management of individual projects or other operational 
        activities.
            ``(4) Report.--On or before July 1 of each year, the 
        Director shall submit a report to the appropriate congressional 
        committees that addresses the following:
                    ``(A) The number of requests received during the 
                previous 12 months, including the identity of each 
                requesting agency and the type of technology requested.
                    ``(B) The number of requests fulfilled during the 
                previous 12 months, including the identity of each 
                recipient agency and the type of technology 
                transferred.
                    ``(C) A summary of the criteria used in making the 
                determination on what requests were funded and what 
                requests were not funded, except that such summary 
                shall not include specific information on any 
                individual requests.
                    ``(D) A general assessment of the future needs of 
                the program, based on expected changes in threats, 
                expected technologies, and likely need from potential 
                recipients.
                    ``(E) An assessment of the effectiveness of the 
                technologies transferred, based in part on the 
                evaluations provided by the recipients, with a 
                recommendation whether the technology should continue 
                to be offered through the program.''.
    (c) Assistance From Secretary of Homeland Security.--Section 708(d) 
(21 U.S.C. 1707(d)) is amended by inserting ``, the Secretary of 
Homeland Security,'' after ``The Secretary of Defense''.

SEC. 112. NATIONAL YOUTH ANTIDRUG MEDIA CAMPAIGN.

    (a) In General.--Section 709 (21 U.S.C. 1708) is amended to read as 
follows:

``SEC. 709. NATIONAL YOUTH ANTIDRUG MEDIA CAMPAIGN.

    ``(a) In General.--The Director shall conduct a national youth 
anti-drug media campaign (referred to in this subtitle as the `national 
media campaign') in accordance with this section for the purposes of--
            ``(1) preventing drug abuse among young people in the 
        United States;
            ``(2) increasing awareness of adults of the impact of drug 
        abuse on young people; and
            ``(3) encouraging parents and other interested adults to 
        discuss with young people the dangers of illegal drug use.
    ``(b) Use of Funds.--
            ``(1) In general.--Amounts made available to carry out this 
        section for the national media campaign may only be used for 
        the following:
                    ``(A) The purchase of media time and space, 
                including the strategic planning for, and accounting 
                of, such purchases.
                    ``(B) Creative and talent costs, consistent with 
                paragraph (2)(A).
                    ``(C) Advertising production costs.
                    ``(D) Testing and evaluation of advertising.
                    ``(E) Evaluation of the effectiveness of the 
                national media campaign.
                    ``(F) The negotiated fees for the winning bidder on 
                requests for proposals issued either by the Office or 
                its designee to enter into contracts to carry out 
                activities authorized by this section.
                    ``(G) Partnerships with professional and civic 
                groups, community-based organizations, including faith-
                based organizations, and government organizations 
                related to the national media campaign.
                    ``(H) Entertainment industry outreach, interactive 
                outreach, media projects and activities, public 
                information, news media outreach, and corporate 
                sponsorship and participation.
                    ``(I) Operational and management expenses.
            ``(2) Specific requirements.--
                    ``(A) Creative services.--
                            ``(i) In using amounts for creative and 
                        talent costs under paragraph (1)(B), the 
                        Director shall use creative services donated at 
                        no cost to the Government (including creative 
                        services provided by the Partnership for a 
                        Drug-Free America) wherever feasible and may 
                        only procure creative services for 
                        advertising--
                                    ``(I) responding to high-priority 
                                or emergent campaign needs that cannot 
                                timely be obtained at no cost; or
                                    ``(II) intended to reach a 
                                minority, ethnic, or other special 
                                audience that cannot reasonably be 
                                obtained at no cost; or
                                    ``(III) the Director determines 
                                that the Partnership for a Drug-Free 
                                America is unable to provide, pursuant 
                                to subsection (d)(2)(B).
                            ``(ii) No more than $1,500,000 may be 
                        expended under this section each fiscal year on 
                        creative services, except that the Director may 
                        expend up to $2,000,000 in a fiscal year on 
                        creative services to meet urgent needs of the 
                        national media campaign with advance approval 
                        from the Committee on Appropriations of the 
                        House of Representatives and of the Senate upon 
                        a showing of the circumstances causing such 
                        urgent needs of the national media campaign.
                    ``(B) Testing and evaluation of advertising.--In 
                using amounts for testing and evaluation of advertising 
                under paragraph (1)(D), the Director shall test all 
                advertisements prior to use in the national media 
                campaign to ensure that the advertisements are 
                effective and meet industry-accepted standards. The 
                Director may waive this requirement for advertisements 
                using no more than 10 percent of the purchase of 
                advertising time purchased under this section in a 
                fiscal year and no more than 10 percent of the 
                advertising space purchased under this section in a 
                fiscal year, if the advertisements respond to emergent 
                and time-sensitive campaign needs or the advertisements 
                will not be widely utilized in the national media 
                campaign.
                    ``(C) Evaluation of effectiveness of media 
                campaign.--In using amounts for the evaluation of the 
                effectiveness of the national media campaign under 
                paragraph (1)(E), the Director shall--
                            ``(i) designate an independent entity to 
                        evaluate annually the effectiveness of the 
                        national media campaign based on data from--
                                    ``(I) the Monitoring the Future 
                                Study published by the Department of 
                                Health and Human Services;
                                    ``(II) the Attitude Tracking Study 
                                published by the Partnership for a Drug 
                                Free America;
                                    ``(III) the National Household 
                                Survey on Drug Abuse; and
                                    ``(IV) other relevant studies or 
                                publications, as determined by the 
                                Director, including tracking and 
                                evaluation data collected according to 
                                marketing and advertising industry 
                                standards; and
                            ``(ii) ensure that the effectiveness of the 
                        national media campaign is evaluated in a 
                        manner that enables consideration of whether 
                        the national media campaign has contributed to 
                        reduction of illicit drug use among youth and 
                        such other measures of evaluation as the 
                        Director determines are appropriate.
            ``(3) Purchase of advertising time and space.--For each 
        fiscal year, not less than 77 percent of the amounts 
        appropriated under this section shall be used for the purchase 
        of advertising time and space for the national media campaign, 
        subject to the following exceptions:
                    ``(A) In any fiscal year for which less than 
                $125,000,000 is appropriated for the national media 
                campaign, not less than 82 percent of the amounts 
                appropriated under this section shall be used for the 
                purchase of advertising time and space for the national 
                media campaign.
                    ``(B) In any fiscal year for which more than 
                $195,000,000 is appropriated under this section, not 
                less than 72 percent shall be used for advertising 
                production costs and the purchase of advertising time 
                and space for the national media campaign.
    ``(c) Advertising.--In carrying out this section, the Director 
shall ensure that sufficient funds are allocated to meet the stated 
goals of the national media campaign.
    ``(d) Division of Responsibilities and Functions Under the 
Program.--
            ``(1) In general.--The Director, in consultation with the 
        Partnership for a Drug-Free America, shall determine the 
        overall purposes and strategy of the national media campaign.
            ``(2) Responsibilities.--
                    ``(A) Director.--The Director shall be responsible 
                for implementing a focused national media campaign to 
                meet the purposes set forth in subsection (a), and 
                shall approve--
                            ``(i) the strategy of the national media 
                        campaign;
                            ``(ii) all advertising and promotional 
                        material used in the national media campaign; 
                        and
                            ``(iii) the plan for the purchase of 
                        advertising time and space for the national 
                        media campaign.
                    ``(B) The partnership for a drug-free america.--The 
                Director shall request that the Partnership for a Drug-
                Free America--
                            ``(i) develop and recommend strategies to 
                        achieve the goals of the national media 
                        campaign, including addressing national and 
                        local drug threats in specific regions or 
                        States, such as methamphetamine and ecstasy;
                            ``(ii) create all advertising to be used in 
                        the national media campaign, except 
                        advertisements that are--
                                    ``(I) provided by other nonprofit 
                                entities pursuant to subsection (f);
                                    ``(II) intended to respond to high-
                                priority or emergent campaign needs 
                                that cannot timely be obtained at no 
                                cost (not including production costs 
                                and talent reuse payments), provided 
                                that any such advertising material is 
                                reviewed by the Partnership for a Drug-
                                Free America;
                                    ``(III) intended to reach a 
                                minority, ethnic, or other special 
                                audience that cannot be obtained at no 
                                cost (not including production costs 
                                and talent reuse payments), provided 
                                that any such advertising material is 
                                reviewed by the Partnership for a Drug-
                                Free America; or
                                    ``(IV) any other advertisements 
                                that the Director determines that the 
                                Partnership for a Drug-Free America is 
                                unable to provide.
                    ``(C) Media buying contractor.--The Director shall 
                enter into a contract with a media buying contractor to 
                plan and purchase advertising time and space for the 
                national media campaign. The media buying contractor 
                shall not provide any other service or material, or 
                conduct any other function or activity which the 
                Director determines should be provided by the 
                Partnership for a Drug-Free America.
    ``(e) Prohibitions.--None of the amounts made available under 
subsection (b) may be obligated or expended for any of the following:
            ``(1) To supplant current antidrug community-based 
        coalitions.
            ``(2) To supplant pro bono public service time donated by 
        national and local broadcasting networks for other public 
        service campaigns.
            ``(3) For partisan political purposes, or express advocacy 
        in support of or to defeat any clearly identified candidate, 
        clearly identified ballot initiative, or clearly identified 
        legislative or regulatory proposal.
            ``(4) To fund advertising that features any elected 
        officials, persons seeking elected office, cabinet level 
        officials, or other Federal officials employed pursuant to 
        section 213 of Schedule C of title 5, Code of Federal 
        Regulations.
            ``(5) To fund advertising that does not contain a primary 
        message intended to reduce or prevent illicit drug use.
            ``(6) To fund advertising containing a primary message 
        intended to promote support for the media campaign or private 
        sector contributions to the media campaign.
    ``(f) Matching Requirement.--
            ``(1) In general.--Amounts made available under subsection 
        (b) for media time and space shall be matched by an equal 
        amount of non-Federal funds for the national media campaign, or 
        be matched with in-kind contributions of the same value.
            ``(2) No-cost match advertising direct relationship 
        requirement.--The Director shall ensure that at least 70 
        percent of no-cost match advertising provided directly relates 
        to substance abuse prevention consistent with the specific 
        purposes of the national media campaign, except that in any 
        fiscal year in which less than $125,000,000 is appropriated to 
        the national media campaign, the Director shall ensure that at 
        least 85 percent of no-cost match advertising directly relates 
        to substance abuse prevention consistent with the specific 
        purposes of the national media campaign.
            ``(3) No-cost match advertising not directly related.--The 
        Director shall ensure that no-cost match advertising that does 
        not directly relate to substance abuse prevention consistent 
        with the purposes of the national media campaign includes a 
        clear antidrug message. Such message is not required to be the 
        primary message of the match advertising.
    ``(g) Financial and Performance Accountability.--The Director shall 
cause to be performed--
            ``(1) audits and reviews of costs of the national media 
        campaign pursuant to section 304C of the Federal Property and 
        Administrative Services Act of 1949 (41 U.S.C. 254d); and
            ``(2) an audit to determine whether the costs of the 
        national media campaign are allowable under section 306 of such 
        Act (41 U.S.C. 256).
    ``(h) Report to Congress.--The Director shall submit on an annual 
basis a report to Congress that describes--
            ``(1) the strategy of the national media campaign and 
        whether specific objectives of the media campaign were 
        accomplished;
            ``(2) steps taken to ensure that the national media 
        campaign operates in an effective and efficient manner 
        consistent with the overall strategy and focus of the national 
        media campaign;
            ``(3) plans to purchase advertising time and space;
            ``(4) policies and practices implemented to ensure that 
        Federal funds are used responsibly to purchase advertising time 
        and space and eliminate the potential for waste, fraud, and 
        abuse; and
            ``(5) all contracts entered into with a corporation, 
        partnership, or individual working on behalf of the national 
        media campaign.
    ``(i) Local Target Requirement.--The Director shall, to the maximum 
extent feasible, use amounts made available under this section for 
media that focuses on, or includes specific information on, prevention 
or treatment resources for consumers within specific local areas.
    ``(j) Prevention of Marijuana Use.--
            ``(1) Findings.--The Congress finds the following:
                    ``(A) 60 percent of adolescent admissions for drug 
                treatment are based on marijuana use.
                    ``(B) Potency levels of contemporary marijuana, 
                particularly hydroponically grown marijuana, are 
                significantly higher than in the past, rising from 
                under 1 percent of THC in the mid-1970s to as high as 
                30 percent today.
                    ``(C) Contemporary research has demonstrated that 
                youths smoking marijuana early in life may be up to 
                five times more likely to use hard drugs.
                    ``(D) Contemporary research has demonstrated clear 
                detrimental effects in adolescent educational 
                achievement resulting from marijuana use.
                    ``(E) Contemporary research has demonstrated clear 
                detrimental effects in adolescent brain development 
                resulting from marijuana use.
                    ``(F) An estimated 9,000,000 Americans a year drive 
                while under the influence of illegal drugs, including 
                marijuana.
                    ``(G) Marijuana smoke contains 50 to 70 percent 
                more of certain cancer causing chemicals than tobacco 
                smoke.
                    ``(H) Teens who use marijuana are up to four times 
                more likely to have a teen pregnancy than teens who 
                have not.
                    ``(I) Federal law enforcement agencies have 
                identified clear links suggesting that trade in 
                hydroponic marijuana facilitates trade by criminal 
                organizations in hard drugs, including heroin.
                    ``(J) Federal law enforcement agencies have 
                identified possible links between trade in cannabis 
                products and financing for terrorist organizations.
            ``(2) Emphasis on prevention of youth marijuana use.--In 
        conducting advertising and activities otherwise authorized 
        under this section, the Director may emphasize prevention of 
        youth marijuana use.
    ``(k) Authorization of Appropriations.--There is authorized to be 
appropriated to the Office to carry out this section, $195,000,000 for 
each of fiscal years 2006 and 2007 and $210,000,000 for each of fiscal 
years 2008 through 2010.''.
    (b) Repeal of Superseded Provisions.--The Drug-Free Media Campaign 
Act of 1998 (21 U.S.C. 1801 et seq.) is repealed.

SEC. 113. DRUG INTERDICTION.

    (a) In General.--Subsections (a) and (b) of section 711 (21 U.S.C. 
1710) are amended to read as follows:
    ``(a) United States Interdiction Coordinator.--
            ``(1) In general.--The Deputy Director for Supply Reduction 
        in the Office shall serve as the United States Interdiction 
        Coordinator, and shall perform the duties of that position 
        described in paragraph (2) and such other duties as may be 
        determined by the Director with respect to coordination of 
        efforts to interdict illicit drugs from entering the United 
        States.
            ``(2) Responsibilities.--The United States Interdiction 
        Coordinator shall be responsible to the Director for--
                    ``(A) coordinating the interdiction activities of 
                the National Drug Control Program agencies to ensure 
                consistency with the National Drug Control Strategy;
                    ``(B) on behalf of the Director, developing and 
                issuing, on or before March 1 of each year and in 
                accordance with paragraph (3), a National Interdiction 
                Command and Control Plan to ensure the coordination and 
                consistency described in subparagraph (A);
                    ``(C) assessing the sufficiency of assets committed 
                to illicit drug interdiction by the relevant National 
                Drug Control Program agencies; and
                    ``(D) advising the Director on the efforts of each 
                National Drug Control Program agency to implement the 
                National Interdiction Command and Control Plan.
            ``(3) Staff.--The Director shall assign such permanent 
        staff of the Office as he considers appropriate to assist the 
        United States Interdiction Coordinator to carry out the 
        responsibilities described in paragraph (2), and may also, at 
        his discretion, request that appropriate National Drug Control 
        Program agencies detail or assign staff to the Office of Supply 
        Reduction for that purpose.
            ``(4) National interdiction command and control plan.--
                    ``(A) Purposes.--The National Interdiction Command 
                and Control Plan shall--
                            ``(i) set forth the Government's strategy 
                        for drug interdiction;
                            ``(ii) state the specific roles and 
                        responsibilities of the relevant National Drug 
                        Control Program agencies for implementing that 
                        strategy; and
                            ``(iii) identify the specific resources 
                        required to enable the relevant National Drug 
                        Control Program agencies to implement that 
                        strategy.
                    ``(B) Consultation with other agencies.--The United 
                States Interdiction Coordinator shall issue the 
                National Interdiction Command and Control Plan in 
                consultation with the other members of the Interdiction 
                Committee described in subsection (b).
                    ``(C) Limitation.--The National Interdiction 
                Command and Control Plan shall not change existing 
                agency authorities or the laws governing interagency 
                relationships, but may include recommendations about 
                changes to such authorities or laws.
                    ``(D) Report to congress.--On or before March 1 of 
                each year, the United States Interdiction Coordinator 
                shall provide a report on behalf of the Director to the 
                appropriate congressional committees, to the Committee 
                on Armed Services and the Committee on Homeland 
                Security of the House of Representatives, and to the 
                Committee on Homeland Security and Governmental Affairs 
                and the Committee on Armed Services of the Senate, 
                which shall include--
                            ``(i) a copy of that year's National 
                        Interdiction Command and Control Plan;
                            ``(ii) information for the previous 10 
                        years regarding the number and type of seizures 
                        of drugs by each National Drug Control Program 
                        agency conducting drug interdiction activities, 
                        as well as statistical information on the 
                        geographic areas of such seizures; and
                            ``(iii) information for the previous 10 
                        years regarding the number of air and maritime 
                        patrol hours undertaken by each National Drug 
                        Control Program agency conducting drug 
                        interdiction activities, as well as statistical 
                        information on the geographic areas in which 
                        such patrol hours took place.
                    ``(E) Treatment of classified or law enforcement 
                sensitive information.--Any content of the report 
                described in subparagraph (D) that involves information 
                classified under criteria established by an Executive 
                order, or the public disclosure of which, as determined 
                by the United States Interdiction Coordinator or the 
                head of any relevant National Drug Control Program 
                agency, would be detrimental to the law enforcement or 
                national security activities of any Federal, State, or 
                local agency, shall be presented to Congress separately 
                from the rest of the plan.
    ``(b) Interdiction Committee.--
            ``(1) In general.--The Interdiction Committee shall meet 
        to--
                    ``(A) discuss and resolve issues related to the 
                coordination, oversight and integration of 
                international, border, and domestic drug interdiction 
                efforts in support of the National Drug Control 
                Strategy;
                    ``(B) review the annual National Interdiction 
                Command and Control Plan, and provide advice to the 
                Director and the United States Interdiction Coordinator 
                concerning that plan; and
                    ``(C) provide such other advice to the Director 
                concerning drug interdiction strategy and policies as 
                the committee determines is appropriate.
            ``(2) Membership.--The membership of the Interdiction 
        Committee shall consist of--
                    ``(A) the Commissioner of the bureau of Customs and 
                Border Protection at the Department of Homeland 
                Security;
                    ``(B) the Assistant Secretary of the bureau of 
                Immigration and Customs Enforcement at the Department 
                of Homeland Security;
                    ``(C) the Commandant of the United States Coast 
                Guard;
                    ``(D) the Director of the Office of 
                Counternarcotics Enforcement at the Department of 
                Homeland Security;
                    ``(E) the Administrator of the Drug Enforcement 
                Administration;
                    ``(F) the Assistant Secretary of State for 
                International Narcotics and Law Enforcement Affairs;
                    ``(G) the Assistant Secretary of Defense for 
                Special Operations and Low Intensity Conflict;
                    ``(H) the Deputy Director for Supply Reduction of 
                the Office of National Drug Control Policy, acting in 
                his role as the United States Interdiction Coordinator;
                    ``(I) the director of the Crime and Narcotics 
                Center of the Central Intelligence Agency;
                    ``(J) the Deputy Director for State and Local 
                Affairs of the Office of National Drug Control Policy;
                    ``(K) the Chief of the National Guard Bureau's 
                Counterdrug Program; and
                    ``(L) such additional persons as may be determined 
                by the Director.
            ``(3) Chairman.--The Director shall designate one of the 
        members of the Interdiction Committee to serve as chairman.
            ``(4) Meetings.--The members of the Interdiction Committee 
        shall meet, in person and not through any delegate or 
        representative, at least once per calendar year, prior to March 
        1. At the call of either the Director or the current chairman, 
        the Interdiction Committee may hold additional meetings, which 
        shall be attended by the members either in person, or through 
        such delegates or representatives as they may choose.
            ``(5) Report.--Not later than September 30 of each year, 
        the chairman of the Interdiction Committee shall submit a 
        report to the Director and to the appropriate congressional 
        committees describing the results of the meetings and any 
        significant findings of the Committee during the previous 12 
        months. Any content of such a report that involves information 
        classified under criteria established by an Executive order, or 
        whose public disclosure, as determined by the Director, the 
        chairman, or any member, would be detrimental to the law 
        enforcement or national security activities of any Federal, 
        State, or local agency, shall be presented to Congress 
        separately from the rest of the report.''.
    (b) Conforming Amendment to Homeland Security Act of 2002.--Section 
878 of the Homeland Security Act of 2002 (6 U.S.C. 458) is amended--
            (1) in subsection (c), by striking ``Except as provided in 
        subsection (d), the'' and inserting ``The''; and
            (2) by striking subsection (d) and redesignating 
        subsections (e), (f), and (g) as subsections (d), (e), and (f), 
        respectively.

SEC. 114. AUTHORIZATION OF APPROPRIATIONS.

    Section 714 (21 U.S.C. 1711) is amended--
            (1) by striking ``title,'' and inserting ``title, except 
        activities for which amounts are otherwise specifically 
        authorized by this title,''; and
            (2) by striking ``1999 through 2003'' and inserting ``2006 
        through 2010''.

SEC. 115. TECHNICAL AMENDMENTS AND REPEAL.

    (a) Amendment to Public Health Service Act to Replace Obsolete 
References.--Section 464P(c) of the Public Health Service Act (42 
U.S.C. 285o-4(c)) is amended--
            (1) in paragraph (1), by striking ``under section 1002 of 
        the Anti-Drug Abuse Act of 1988 (21 U.S.C. 1501)'' and 
        inserting ``under section 703 of the Office of National Drug 
        Control Policy Reauthorization Act of 1998 (21 U.S.C. 1702)''; 
        and
            (2) in paragraph (2), by striking ``under section 1005 of 
        the Anti-Drug Abuse Act of 1988 (21 U.S.C. 1504)'' and 
        inserting ``under section 706 of the Office of National Drug 
        Control Policy Reauthorization Act of 1998 (21 U.S.C. 1705)''.
    (b) Repeal of Special Forfeiture Fund.--Section 6073 of the Asset 
Forfeiture Amendments Act of 1988 (21 U.S.C. 1509) is repealed.

SEC. 116. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSORSHIP OF ALL 
              FEDERAL ADVERTISING OR OTHER COMMUNICATION MATERIALS.

    Section 712 is amended to read as follows:

``SEC. 712. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSORSHIP OF ALL 
              FEDERAL ADVERTISING OR OTHER COMMUNICATION MATERIALS.

    ``(a) Requirement.--Each advertisement or other communication paid 
for by the Office, either directly or through a contract awarded by the 
Office, shall include a prominent notice informing the target audience 
that the advertisement or other communication is paid for by the 
Office.
    ``(b) Advertisement or Other Communication.--In this section, the 
term `advertisement or other communication' includes--
            ``(1) an advertisement disseminated in any form, including 
        print or by any electronic means; and
            ``(2) a communication by an individual in any form, 
        including speech, print, or by any electronic means.''.

SEC. 117. POLICY RELATING TO SYRINGE EXCHANGE PROGRAMS.

    Section 703(a) (21 U.S.C. 1702(a)) is amended by adding at the end 
the following:
``When developing the national drug control policy, any policy of the 
Director relating to syringe exchange programs for intravenous drug 
users shall be based on the best available medical and scientific 
evidence regarding their effectiveness in promoting individual health 
and preventing the spread of infectious disease, and their impact on 
drug addiction and use. In making any policy relating to syringe 
exchange programs, the Director shall consult with the National 
Institutes of Health and the National Academy of Sciences.''.

         <DELETED>TITLE II--CLEAN SPORTS ACT OF 2005</DELETED>

<DELETED>SEC. 201. ADDITION OF MINIMUM DRUG TESTING STANDARDS TO OFFICE 
              OF NATIONAL DRUG CONTROL POLICY ACT.</DELETED>

<DELETED>    (a) Amendment.--The Office of National Drug Control Policy 
Reauthorization Act of 1998 (Public Law 105-277; 21 U.S.C. 1701 et 
seq.) is amended--</DELETED>
        <DELETED>    (1) by inserting before section 701 the 
        following:</DELETED>

   <DELETED>``Subtitle A--Office of National Drug Control Policy''; 
                             and</DELETED>

        <DELETED>    (2) by adding at the end the following new 
        subtitle:</DELETED>

       <DELETED>``Subtitle B--Clean Sports Act of 2005</DELETED>

<DELETED>``SEC. 721. SHORT TITLE.</DELETED>

<DELETED>    ``This subtitle may be cited as the `Clean Sports Act of 
2005'.</DELETED>

<DELETED>``SEC. 722. FINDINGS AND PURPOSE.</DELETED>

<DELETED>    ``(a) Findings.--Congress finds the following:</DELETED>
        <DELETED>    ``(1) The use of anabolic steroids and other 
        performance-enhancing substances by minors is a public health 
        problem of national significance.</DELETED>
        <DELETED>    ``(2) Experts estimate that over 500,000 teenagers 
        have used performance-enhancing substances, which medical 
        experts warn can cause a litany of health problems for 
        individuals who take them, in particular children and 
        teenagers.</DELETED>
        <DELETED>    ``(3) The adverse health effects caused by 
        steroids and other performance-enhancing substances include 
        stunted growth, scarring acne, hair loss, dramatic mood swings, 
        hormonal and metabolic imbalances, liver damage, a higher risk 
        of heart disease and stroke later in life, as well as an 
        increased propensity to demonstrate aggressive behavior, commit 
        suicide, and commit crimes.</DELETED>
        <DELETED>    ``(4) Professional athletes are role models for 
        young athletes and influence the behavior of children and 
        teenagers.</DELETED>
        <DELETED>    ``(5) Congressional testimony by parents of minors 
        who used performance enhancing drugs, as well as medical and 
        health experts, indicates that the actual or alleged use of 
        performance-enhancing substances by professional athletes 
        results in the increased use of these substances by children 
        and teenagers.</DELETED>
        <DELETED>    ``(6) Surveys and studies suggest a connection 
        between the actual or alleged use of performance-enhancing 
        substances by college and professional athletes and the 
        increased use of these substances by children and 
        teenagers.</DELETED>
        <DELETED>    ``(7) The real or perceived tolerance of the use 
        of performance-enhancing substances by professional athletes 
        has resulted in both increased pressure on children and 
        teenagers to use performance-enhancing drugs in order to 
        advance their athletic careers and to professional sports loss 
        of integrity.</DELETED>
        <DELETED>    ``(8) The adoption by professional sports leagues 
        of strong policies to eliminate the use of performance-
        enhancing substances would result in the reduced use of these 
        substances by children and teenagers.</DELETED>
        <DELETED>    ``(9) Minimum drug testing standards for 
        professional sports established by Federal law would ensure the 
        adoption of strong policies to eliminate the use of 
        performance-enhancing substances in professional 
        sports.</DELETED>
        <DELETED>    ``(10) Minimum drug testing standards for 
        professional sports established by Federal law would help 
        return integrity to professional sports.</DELETED>
        <DELETED>    ``(11) Congress has for several years expressed a 
        strong interest in the problem of the role of performance-
        enhancing drugs in professional sports and other levels of 
        sports.</DELETED>
        <DELETED>    ``(12) Congress has for several years regulated 
        the use of anabolic steroids and other performance-enhancing 
        substances.</DELETED>
        <DELETED>    ``(13) Recent Federal laws regulating the use of 
        anabolic steroids and other performance-enhancing substances 
        were enacted in large part to reduce the prevalence of these 
        substances in sports.</DELETED>
        <DELETED>    ``(14) Congress has for several years regulated 
        both professional and amateur sports.</DELETED>
<DELETED>    ``(b) Purpose.--The purpose of this subtitle is to protect 
the integrity of professional sports and the health and safety of 
athletes generally by establishing minimum standards for the testing of 
steroids and other performance-enhancing substances by professional 
sports leagues.</DELETED>

<DELETED>``SEC. 723. DEFINITIONS.</DELETED>

<DELETED>    ``In this subtitle:</DELETED>
        <DELETED>    ``(1) Anti-doping code.--The term `anti-doping 
        code' means the doping control standards established in the 
        United States Anti-Doping Agency Protocol for Olympic Movement 
        Testing (excluding substances or methods prohibited in a 
        particular sport, as defined in such protocol).</DELETED>
        <DELETED>    ``(2) Commission.--The term `Commission' means the 
        Federal Trade Commission.</DELETED>
        <DELETED>    ``(3) Director.--The term `Director' means the 
        Director of the Office of National Drug Control 
        Policy.</DELETED>
        <DELETED>    ``(4) Major professional league.--The term `major 
        professional league' means Major League Baseball, the National 
        Basketball Association, the National Football League, and the 
        National Hockey League or any successor organization to those 
        leagues.</DELETED>
        <DELETED>    ``(5) Off-season.--The term `off-season' means the 
        period of time in each calendar year outside of the season of 
        play for each major professional league.</DELETED>
        <DELETED>    ``(6) Professional athlete.--The term 
        `professional athlete' means an individual who competes in a 
        major professional league.</DELETED>
        <DELETED>    ``(7) Professional game.--The term `professional 
        game' means any game held in the United States between any 
        professional teams of a major professional league.</DELETED>
        <DELETED>    ``(8) Prohibited method or substance.--</DELETED>
                <DELETED>    ``(A) Prohibited method.--The term 
                `prohibited method' means a method listed and described 
                in the Anti-Doping Code.</DELETED>
                <DELETED>    ``(B) Prohibited substance.--The term 
                `prohibited substance' means a substance listed and 
                described in the Anti-Doping Code.</DELETED>
                <DELETED>    ``(C) Period of prohibition.--A substance 
                prohibited in-competition by the Anti-Doping Code shall 
                be a prohibited substance only during the season of 
                play. Only a substance or method prohibited out-of-
                competition by the Anti-Doping Code shall be a 
                prohibited substance or method during the off-
                season.</DELETED>
        <DELETED>    ``(9) Season of play.--</DELETED>
                <DELETED>    ``(A) In general.--The term `season of 
                play' for each major professional league means the 
                period of time in each calendar year beginning with the 
                date on which professional athletes of that major 
                professional league are collectively obligated to 
                report to their teams in preparation for play and 
                ending with the last game of the major professional 
                league's regular season.</DELETED>
                <DELETED>    ``(B) Post-season.--The season of play 
                shall include post-season play for an athlete who is a 
                member of a team that remains active in post-season 
                play.</DELETED>

<DELETED>``SEC. 724. MINIMUM UNIFORM TESTING STANDARDS.</DELETED>

<DELETED>    ``(a) Conduct Prohibited.--It shall be unlawful for a 
major professional league to arrange, promote, organize, or produce a 
professional game without meeting the requirements in subsection 
(b).</DELETED>
<DELETED>    ``(b) Minimum Testing Requirements.--Each major 
professional league shall implement policies and procedures for the 
testing of the use of prohibited substances by professional athletes 
who compete in each respective major professional league which shall be 
independently administered and shall be consistent with and as 
stringent as the doping control standard established by the United 
States Anti-Doping Agency, and which shall, at minimum, include the 
following:</DELETED>
        <DELETED>    ``(1) Timing and frequency of testing.--</DELETED>
                <DELETED>    ``(A) In general.--Each professional 
                athlete shall be tested a minimum of 5 times each 
                calendar year that such athlete is competing in games 
                organized by the major professional league.</DELETED>
                <DELETED>    ``(B) Timing.--Each athlete shall be 
                tested--</DELETED>
                        <DELETED>    ``(i) at least 3 times, each with 
                        no advance notice, during each season of play; 
                        and</DELETED>
                        <DELETED>    ``(ii) at least 2 times, each with 
                        no advance notice, during the off-
                        season.</DELETED>
        <DELETED>    ``(2) Test distribution planning.--Each major 
        professional league shall certify to the Director on or prior 
        to December 31 of each year that it has consulted with the 
        United States Anti-Doping Agency in the development of its test 
        distribution plan for both season of play and off-season 
        testing.</DELETED>
        <DELETED>    ``(3) Method of testing.--Each major professional 
        league shall certify to the Director on or prior to December 31 
        of each year that it has consulted with the United States Anti-
        Doping Agency in the development of its drug testing protocols 
        for both season of play and off-season testing.</DELETED>
        <DELETED>    ``(4) Applicable substances.--Each professional 
        athlete shall be tested for all prohibited substances at the 
        time of each test. A major professional league may make 
        exceptions for any prohibited substances that have been 
        properly prescribed by a doctor of medicine licensed in the 
        United States for legitimate and documented therapeutic 
        purposes.</DELETED>
        <DELETED>    ``(5) Analysis of sample.--Each sample provided 
        shall be analyzed by a laboratory approved by the United States 
        Anti-Doping Agency.</DELETED>
        <DELETED>    ``(6) Positive tests.--</DELETED>
                <DELETED>    ``(A) In general.--A positive test shall 
                consist of the presence in the sample of any prohibited 
                substance or its metabolites or markers, or evidence of 
                the use of a prohibited method, unless that substance 
                was prescribed to the athlete in accordance with 
                paragraph (4).</DELETED>
                <DELETED>    ``(B) Refusal.--A refusal by a 
                professional athlete to submit to a test or a failure 
                of a professional athlete to submit to a test without 
                compelling justification shall also be considered a 
                positive test.</DELETED>
        <DELETED>    ``(7) Penalties.--</DELETED>
                <DELETED>    ``(A) General rule.--</DELETED>
                        <DELETED>    ``(i) First violation.--Except as 
                        provided in subparagraph (B), a professional 
                        athlete who tests positive shall be immediately 
                        suspended for a minimum of 2 years for a first 
                        violation. All suspensions shall include a loss 
                        of pay for the period of the 
                        suspension.</DELETED>
                        <DELETED>    ``(ii) Second violation.--A second 
                        violation shall result in a lifetime ban of the 
                        professional athlete from all major 
                        professional leagues.</DELETED>
                <DELETED>    ``(B) Exceptions.--</DELETED>
                        <DELETED>    ``(i) Knowledge of the athlete.--A 
                        major professional league may impose a lesser 
                        penalty than provided in subparagraph (A) or no 
                        penalty if the professional athlete establishes 
                        that he did not know or suspect, and could not 
                        reasonably have known or suspected even with 
                        the exercise of utmost caution, that he had 
                        used the prohibited substance.</DELETED>
                        <DELETED>    ``(ii) Assistance in identifying 
                        violations.--A major professional league may 
                        impose a lesser penalty than provided in 
                        subparagraph (A) if the professional athlete 
                        provides substantial assistance to the major 
                        professional league in identifying violations 
                        of the league's drug testing policy by other 
                        professional athletes or assistance in 
                        violations of the league's drug testing policy 
                        by any coach, trainer, manager, agent, team 
                        staff, official, medical, or other personnel 
                        working with or treating professional athletes 
                        participating in or preparing for sports 
                        competition.</DELETED>
        <DELETED>    ``(8) Adjudication.--</DELETED>
                <DELETED>    ``(A) Consultation.--Each major 
                professional league shall certify to the Director on or 
                prior to December 31 of each year that it has consulted 
                with the United States Anti-Doping Agency in the 
                development of its adjudication process.</DELETED>
                <DELETED>    ``(B) Due process.--If a professional 
                athlete tests positive, the professional athlete shall 
                have the right to notice, a fair, timely, and expedited 
                hearing, representation by counsel and 
                appeal.</DELETED>
                <DELETED>    ``(C) Suspension.--During the pendency of 
                any proceedings the professional athlete shall be 
                suspended from participating in any professional 
                game.</DELETED>
        <DELETED>    ``(9) Public disclosure.--</DELETED>
                <DELETED>    ``(A) Testing.--A major professional 
                league shall publicly disclose the identity of any 
                professional player who has tested positive as well as 
                the prohibited substance or prohibited method for which 
                he tested positive not later than 30 days after 
                receiving the test results.</DELETED>
                <DELETED>    ``(B) Penalty.--A major professional 
                league shall publicly disclose the name of any 
                penalized athlete, the penalty imposed, the substance 
                for which the player tested positive, and the reason 
                for the penalty not later than 15 days after the final 
                disposition of the player's case.</DELETED>

<DELETED>``SEC. 725. PROMULGATION OF STANDARDS BY THE DIRECTOR OF THE 
              OFFICE OF NATIONAL DRUG CONTROL POLICY.</DELETED>

<DELETED>    ``(a) In General.--The Director shall have the authority 
to promulgate standards that would modify the provisions of section 724 
as they apply to an individual major professional league for 
exceptional circumstances or for other good cause.</DELETED>
<DELETED>    ``(b) Effectiveness Maintained.--A modification under 
subsection (a) shall not--</DELETED>
        <DELETED>    ``(1) reduce the effectiveness of the standards in 
        eliminating the use of steroids or other performance-enhancing 
        substances in any major professional league; or</DELETED>
        <DELETED>    ``(2) diminish the leadership role of the United 
        States in eliminating the use of steroids or other performance-
        enhancing substances in sports.</DELETED>
<DELETED>    ``(c) Inclusion of Additional Leagues.--The Director may 
include an additional professional sporting league or the colleges and 
athletes participating in Division I or Division II of the NCAA as a 
major professional league if the Director determines that such 
additions would prevent the use of performance-enhancing substances by 
high school, college, or professional athletes.</DELETED>
<DELETED>    ``(d) Delegation.--The Director may delegate the 
administration of this subtitle to any other appropriate agency of the 
Federal Government.</DELETED>

<DELETED>``SEC. 726. ENFORCEMENT BY THE FEDERAL TRADE 
              COMMISSION.</DELETED>

<DELETED>    ``(a) Unfair or Deceptive Acts or Practices.--A violation 
of section 724 shall be treated as a violation of section 18 of the 
Federal Trade Commission Act (15 U.S.C. 57a) regarding unfair or 
deceptive acts or practices.</DELETED>
<DELETED>    ``(b) Powers of Commission.--</DELETED>
        <DELETED>    ``(1) In general.--The Commission shall issue and 
        enforce the regulations for the enforcement of section 724 in 
        the same manner, by the same means, and with the same 
        jurisdiction, powers, and duties as though all applicable terms 
        and provisions of the Federal Trade Commission Act (15 U.S.C. 
        41 et seq.) were incorporated into and made a part of this 
        subtitle. Any person who violates such regulations shall be 
        subject to the penalties and entitled to the privileges and 
        immunities provided in that Act.</DELETED>
        <DELETED>    ``(2) Enhanced penalty for violations.--
        Notwithstanding subsection (a) and the Federal Trade Commission 
        Act, in the case of a person who violates section 724, the 
        Commission may, in its discretion, seek a civil penalty for 
        such violation in an amount, as determined by the Commission, 
        of not more than $1,000,000 for each violation of section 
        724.</DELETED>
        <DELETED>    ``(3) General authority.--Nothing in this subtitle 
        shall be construed to limit the authority of the Commission 
        under any other provision of law.</DELETED>

<DELETED>``SEC. 727. REPORTS TO CONGRESS.</DELETED>

<DELETED>    ``(a) First League Report.--</DELETED>
        <DELETED>    ``(1) In general.--Not later than 6 months after 
        completion of a professional sports league's first season of 
        play after the effective date of this subtitle, each major 
        professional league shall transmit to the Committee on 
        Commerce, Science, and Transportation of the Senate and the 
        Committee on Energy and Commerce and the Committee on 
        Government Reform of the House of Representatives, a report on 
        its testing policies and procedures.</DELETED>
        <DELETED>    ``(2) Contents.--The report required by this 
        subsection shall contain--</DELETED>
                <DELETED>    ``(A) a comparison of the major 
                professional league's testing policy (including its 
                adjudication procedures) to that of the United States 
                Anti-Doping Agency, emphasizing the differences between 
                the policies and the rationales for the differences; 
                and</DELETED>
                <DELETED>    ``(B) aggregate data on the number of 
                professional players tested by the major professional 
                league and the prohibited substances detected in 
                samples or prohibited methods, including the number of 
                tests conducted during the season of play and during 
                the off-season.</DELETED>
<DELETED>    ``(b) Biennial League Reports.--Each major professional 
league shall transmit to the Committee on Commerce, Science, and 
Transportation of the Senate and the Committee on Energy and Commerce 
and the Committee on Government Reform of the House of Representatives, 
on a biennial basis, a report containing the data and analysis required 
in subsection (a) for each of the 2 prior years.</DELETED>
<DELETED>    ``(c) ONDCP Report.--Not later than 1 year after the date 
of enactment of this subtitle, and subsequently thereafter as 
determined appropriate by the Director, the Director shall report to 
the Committee on Commerce, Science, and Transportation of the Senate 
and the Committee on Energy and Commerce and the Committee on 
Government Reform of the House of Representatives, recommendations for 
improving any Federal law governing controlled substances as may be 
necessary for reducing the use of steroids and other performance-
enhancing substances.</DELETED>

<DELETED>``SEC. 728. PROMULGATION OF STANDARDS BY UNITED STATES BOXING 
              COMMISSION.</DELETED>

<DELETED>    ``Upon the later of 12 months after enactment of this 
subtitle or 12 months after the establishment of the United States 
Boxing Commission pursuant to Federal law, that commission shall, in 
consultation with the Association of Boxing Commissions and the United 
States Anti-Doping Agency, promulgate uniform performance-enhancing 
substance testing standards for professional boxing that are consistent 
with section 724.</DELETED>

<DELETED>``SEC. 729. STUDY ON COLLEGE TESTING POLICIES AND 
              PROCEDURES.</DELETED>

<DELETED>    ``(a) Study.--The Government Accountability Office shall 
conduct a study on the use of performance-enhancing substances by 
college athletes which shall examine the prohibited substance policies 
and testing procedures of intercollegiate athletic associations and 
college and university athletic departments.</DELETED>
<DELETED>    ``(b) Report.--</DELETED>
        <DELETED>    ``(1) Submission to congress.--Not later than 1 
        year after the date of enactment of this subtitle, the 
        Government Accountability Office shall transmit a report to the 
        Committee on Commerce, Science, and Transportation of the 
        Senate and the Committee on Energy and Commerce and the 
        Committee on Government Reform of the House of 
        Representatives.</DELETED>
        <DELETED>    ``(2) Contents.--The report required by this 
        subsection shall--</DELETED>
                <DELETED>    ``(A) assess the adequacy of the testing 
                policies and procedures described in subsection (a) in 
                detecting and preventing the use of performance-
                enhancing substances; and</DELETED>
                <DELETED>    ``(B) include recommendations to Congress 
                regarding expanding the application of the regulations 
                issued pursuant to this subtitle to such 
                intercollegiate and interscholastic athletic 
                associations.</DELETED>

<DELETED>``SEC. 730. COMMISSION ON HIGH SCHOOL AND COLLEGIATE 
              ATHLETICS.</DELETED>

<DELETED>    ``(a) Commission.--The Director shall establish a 
commission on high school and collegiate athletics.</DELETED>
<DELETED>    ``(b) Report.--Not later than 1 year after the date of 
enactment of this subtitle, the commission shall report to Congress--
</DELETED>
        <DELETED>    ``(1) findings on the use of steroids and other 
        performance-enhancing substances in high school and collegiate 
        sports; and</DELETED>
        <DELETED>    ``(2) recommendations for reducing their 
        use.</DELETED>

<DELETED>``SEC. 731. SENSE OF CONGRESS.</DELETED>

<DELETED>    ``It is the sense of Congress that--</DELETED>
        <DELETED>    ``(1) professional sports leagues not regulated by 
        this subtitle should adhere to the drug testing standards 
        established in this subtitle;</DELETED>
        <DELETED>    ``(2) all professional sports should implement 
        policies and procedures for the testing of the use of 
        prohibited substances or the detection of prohibited methods by 
        professional athletes that ensure that American professional 
        sports leagues are world leaders in the effort to keep steroids 
        and other performance-enhancing drugs out of sports;</DELETED>
        <DELETED>    ``(3) all professional sports should implement 
        policies and procedures that address the development of 
        designer steroids and emerging methods for doping, including 
        gene doping, that enhance sports performance, are potential or 
        actual health risks, and are contrary to the spirit of the 
        sport; and</DELETED>
        <DELETED>    ``(4) each major professional league should 
        produce and publicize public service announcements regarding 
        the health and safety consequences of steroids and other 
        similar performance-enhancing substances on children and 
        teenagers.</DELETED>

<DELETED>``SEC. 732. EFFECTIVE DATE.</DELETED>

<DELETED>    ``This subtitle shall take effect 1 year after the date of 
enactment of this subtitle.''.</DELETED>
<DELETED>    (b) Conforming Amendments.--The Office of National Drug 
Control Policy Reauthorization Act of 1998 (Public Law 105-277; 21 
U.S.C. 1701 et seq.) is further amended by striking ``title'' each 
place it appears and inserting ``subtitle''--</DELETED>
        <DELETED>    (1) in section 701;</DELETED>
        <DELETED>    (2) in section 702;</DELETED>
        <DELETED>    (3) in section 703(b)(2);</DELETED>
        <DELETED>    (4) in section 704(d)(1); and</DELETED>
        <DELETED>    (5) in the first and second sentences of section 
        705(a)(2)(A).</DELETED>

SECTION 1. SHORT TITLE; TABLE OF CONTENTS.

    (a) Short Title.--This Act may be cited as the ``Office of National 
Drug Control Policy Reauthorization Act of 2005''.
    (b) Table of Contents.--The table of contents for this Act is as 
follows:

Sec. 1. Short title; table of contents.
Sec. 2. Amendment of Office of National Drug Control Policy 
                            Reauthorization Act of 1998.
Sec. 3. Repeal of termination provision.
Sec. 4. Amendments to definitions.
Sec. 5. Amendments relating to establishment of Office of National Drug 
                            Control Policy and designation of officers.
Sec. 6. Amendments relating to appointment and duties of Director and 
                            Deputy Director.
Sec. 7. Amendments relating to coordination with other agencies.
Sec. 8. Development, submission, implementation, and assessment of 
                            National Drug Control Strategy.
Sec. 9. High Intensity Drug Trafficking Areas Program.
Sec. 10. Funding for certain High Intensity Drug Trafficking Areas.
Sec. 11. Amendments relating to Counter-Drug Technology Assessment 
                            Center.
Sec. 12. National youth antidrug media campaign.
Sec. 13. Drug interdiction.
Sec. 14. Awards for demonstration programs by local partnerships to 
                            shut down illicit drug market hot-spots by 
                            deterring drug dealers or altering the 
                            dynamic of drug sales.
Sec. 15. Awards for demonstration programs by local partnerships to 
                            coerce abstinence in chronic hard-drug 
                            users under community supervision through 
                            the use of drug testing and sanctions.
Sec. 16. Authorization of appropriations.
Sec. 17. Technical amendments and repeal.
Sec. 18. Requirement for disclosure of Federal sponsorship of all 
                            Federal advertising or other communication 
                            materials.
Sec. 19. Policy relating to syringe exchange programs.

SEC. 2. AMENDMENT OF OFFICE OF NATIONAL DRUG CONTROL POLICY 
              REAUTHORIZATION ACT OF 1998.

    Except as otherwise expressly provided, whenever in this Act an 
amendment or repeal is expressed in terms of an amendment to, or repeal 
of, a section or other provision, the reference shall be considered to 
be made to a section or other provision of the Office of National Drug 
Control Policy Reauthorization Act of 1998 (Public Law 105-277; 21 
U.S.C. 1701 et seq.).

SEC. 3. REPEAL OF TERMINATION PROVISION.

    Section 715 (21 U.S.C. 1712) is repealed, and the law shall read as 
if such section was never in effect.

SEC. 4. AMENDMENTS TO DEFINITIONS.

    (a) Amendments to Definitions.--Section 702 (21 U.S.C. 1701) is 
amended--
            (1) in paragraph (1)--
                    (A) by striking ``and'' at the end of subparagraph 
                (F);
                    (B) by striking the period at the end of 
                subparagraph (G) and inserting ``, including the 
                testing of employees;''; and
                    (C) by adding at the end the following:
                    ``(H) interventions for drug abuse and dependence; 
                and
                    ``(I) international drug control coordination and 
                cooperation with respect to activities described in 
                this paragraph.'';
            (2) in paragraph (6), by adding before the period at the 
        end: ``, including any activities involving supply reduction, 
        demand reduction, or State and local affairs'';
            (3) in paragraph (7)--
                    (A) by striking ``Agency'' and inserting 
                ``agency'';
                    (B) by striking ``National Foreign Intelligence 
                Program,'' and inserting ``National Intelligence 
                Program,''; and
                    (C) by inserting a comma before ``or Tactical'';
            (4) in paragraph (9), by striking ``implicates'' and 
        inserting ``indicates'';
            (5) in paragraph (10)--
                    (A) by adding ``National Drug Control Program 
                agencies and'' after ``among'' in subparagraph (B);
                    (B) by striking ``and'' at the end of subparagraph 
                (B);
                    (C) by striking the period at the end of 
                subparagraph (C) and inserting a semicolon; and
                    (D) by adding at the end the following:
                    ``(D) domestic drug law enforcement, including 
                domestic drug interdiction and law enforcement directed 
                at drug users; and
                    ``(E) coordination and enhancement of Federal, 
                State, and local law enforcement initiatives to gather, 
                analyze, and disseminate information and intelligence 
                relating to drug control among domestic law enforcement 
                agencies.'';
            (6) in paragraph (11)--
                    (A) by inserting before the semicolon in 
                subparagraph (A) the following: ``, including--
                            ``(i) law enforcement outside the United 
                        States; and
                            ``(ii) source country programs, including 
                        economic development programs primarily 
                        intended to reduce the production or 
                        trafficking of illicit drugs'';
                    (B) by striking subparagraph (B) and inserting the 
                following:
                    ``(B) facilitating and enhancing the sharing of 
                foreign and domestic information and law enforcement 
                intelligence relating to drug production and 
                trafficking among National Drug Control Program 
                agencies, and between those agencies and foreign law 
                enforcement agencies; and'';
                    (C) by striking ``; and'' at the end of 
                subparagraph (C) and inserting a period; and
                    (D) by striking subparagraph (D); and
            (7) by adding at the end the following:
            ``(12) Appropriate congressional committees.--Except where 
        otherwise provided, the term `appropriate congressional 
        committees' means the Committee on the Judiciary, the Committee 
        on Appropriations, and the Caucus on International Narcotics 
        Control of the Senate and the Committee on Government Reform, 
        the Committee on the Judiciary, and the Committee on 
        Appropriations of the House of Representatives.
            ``(13) Law enforcement.--The term `law enforcement' or 
        `drug law enforcement' means all efforts by a Federal, State, 
        or local government agency to enforce the drug laws of the 
        United States or any State, including investigation, arrest, 
        prosecution, and incarceration or other punishments or 
        penalties.''.
    (b) Conforming Amendments.--Section 703(b)(3) (21 U.S.C. 
1702(b)(3)) is amended--
            (1) in subparagraph (A), by striking ``(G)'' and inserting 
        ``(I)''; and
            (2) in subparagraph (C)--
                    (A) by striking ``through (C)'' and inserting 
                ``through (E)'';
                    (B) by striking ``and subparagraph (D) of section 
                702(11)''; and
                    (C) by adding before the period at the end the 
                following: ``, and sections 707 and 708 of this Act''.

SEC. 5. AMENDMENTS RELATING TO ESTABLISHMENT OF OFFICE OF NATIONAL DRUG 
              CONTROL POLICY AND DESIGNATION OF OFFICERS.

    (a) Responsibilities.--Paragraph (4) of section 703(a) (21 U.S.C. 
1702(a)) is amended to read as follows:
            ``(4) evaluate the effectiveness of the national drug 
        control policy and the National Drug Control Program agencies' 
        programs, by developing and applying specific goals and 
        performance measurements.''.
    (b) Rank of Director.--Section 703(b) (21 U.S.C. 1702(b)) is 
amended in paragraph (1) by adding before the period the following: ``, 
who shall hold the same rank and status as the head of an executive 
department listed in section 101 of title 5, United States Code''.
    (c) Deputy Directors.--Section 703(b) (21 U.S.C. 1702(b)) is 
amended in paragraph (3)--
            (1) by striking ``Office--'' and inserting ``Office the 
        following additional Deputy Directors--''; and
            (2) in subparagraph (B), by striking ``who shall'' and 
        inserting the following: ``who shall have substantial 
        experience and expertise in drug interdiction operations and 
        other supply reduction activities, and who shall serve as the 
        United States Interdiction Coordinator and''.

SEC. 6. AMENDMENTS RELATING TO APPOINTMENT AND DUTIES OF DIRECTOR AND 
              DEPUTY DIRECTOR.

    (a) Designation of Other Officers.--Section 704(a)(3) (21 U.S.C. 
1703(a)(3)) is amended--
            (1) by striking ``permanent employee'' and inserting 
        ``officer or employee''; and
            (2) by striking ``serve as the Director'' and inserting 
        ``serve as the acting Director''.
    (b) Responsibilities of Director.--Section 704(b) (21 U.S.C. 
1703(b)) is amended--
            (1) in paragraph (4), by striking ``Federal departments and 
        agencies engaged in drug enforcement,'' and inserting 
        ``National Drug Control Program agencies,'';
            (2) in paragraph (7), by inserting after ``President'' the 
        following: ``and the appropriate congressional committees'';
            (3) in paragraph (13), by striking ``(beginning in 1999)'';
            (4) in paragraph (14)--
                    (A) by striking ``Appropriations'' and all that 
                follows through ``Senate'' and inserting ``appropriate 
                congressional committees''; and
                    (B) by striking ``and'' after the semicolon at the 
                end;
            (5) in paragraph (15), by striking subparagraph (C) and 
        inserting the following:
                    ``(C) supporting the substance abuse information 
                clearinghouse administered by the Administrator of the 
                Substance Abuse and Mental Health Services 
                Administration and established in section 501(d)(16) of 
                the Public Health Service Act by--
                            ``(i) encouraging all National Drug Control 
                        Program agencies to provide all appropriate and 
                        relevant information; and
                            ``(ii) supporting the dissemination of 
                        information to all interested entities;''; and
            (6) by inserting at the end the following:
            ``(16) shall coordinate with the private sector to promote 
        private research and development of medications to treat 
        addiction;
            ``(17) shall seek the support and commitment of State and 
        local officials in the formulation and implementation of the 
        National Drug Control Strategy;
            ``(18) shall monitor and evaluate the allocation of 
        resources among Federal law enforcement agencies in response to 
        significant local and regional drug trafficking and production 
        threats;
            ``(19) shall submit an annual report to Congress detailing 
        how the Office of National Drug Control Policy has consulted 
        with and assisted State and local governments with respect to 
        the formulation and implementation of the National Drug Control 
        Strategy and other relevant issues; and
            ``(20) shall, within one year after the date of the 
        enactment of the Office of National Drug Control Policy 
        Reauthorization Act of 2005, report to Congress on the impact 
        of each Federal drug reduction strategy upon the availability, 
        addiction rate, use rate, and other harms of illegal drugs.''.
    (c) Submission of Drug Control Budget Requests.--Section 704(c)(1) 
is amended by adding at the end the following:
                    ``(C) Content of drug control budget requests.--A 
                drug control budget request submitted by a department, 
                agency, or program under this paragraph shall include 
                all requests for funds for any drug control activity 
                undertaken by that department, agency, or program, 
                including demand reduction, supply reduction, and State 
                and local affairs, including any drug law enforcement 
                activities. If an activity has both drug control and 
                nondrug control purposes or applications, the 
                department, agency, or program shall estimate by a 
                documented calculation the total funds requested for 
                that activity that would be used for drug control, and 
                shall set forth in its request the basis and method for 
                making the estimate.''.
    (d) National Drug Control Budget Proposal.--Section 704(c)(2) is 
amended in subparagraph (A) by inserting before the semicolon: ``and to 
inform Congress and the public about the total amount proposed to be 
spent on all supply reduction, demand reduction, State and local 
affairs, including any drug law enforcement, and other drug control 
activities by the Federal Government, which shall conform to the 
content requirements set forth in subparagraph (C) of paragraph (1) of 
this subsection''.
    (e) Review and Certification of National Drug Control Program 
Budget.--Section 704(c)(3) (21 U.S.C. 1703(c)(3)) is amended--
            (1) by redesignating subparagraphs (C) and (D) as 
        subparagraphs (D) and (E), respectively;
            (2) by inserting after subparagraph (B) the following new 
        subparagraph:
                    ``(C) Specific requests.--The Director shall not 
                confirm the adequacy of any budget request that--
                            ``(i) requests funding for Federal law 
                        enforcement activities that do not adequately 
                        compensate for transfers of drug enforcement 
                        resources and personnel to law enforcement and 
                        investigation activities not related to drug 
                        enforcement as determined by the Director;
                            ``(ii) requests funding for law enforcement 
                        activities on the borders of the United States 
                        that do not adequately direct resources to drug 
                        interdiction and enforcement as determined by 
                        the Director;
                            ``(iii) requests funding for drug treatment 
                        activities that do not provide adequate result 
                        and accountability measures as determined by 
                        the Director;
                            ``(iv) requests funding for any activities 
                        of the Safe and Drug Free Schools Program that 
                        do not include a clear antidrug message or 
                        purpose intended to reduce drug use;
                            ``(v) requests funding to enforce section 
                        484(r)(1) of the Higher Education Act of 1965 
                        (20 U.S.C. 1091(r)(1)) with respect to 
                        convictions for drug-related offenses not 
                        occurring during a period of enrollment for 
                        which the student was receiving any Federal 
                        grant, loan, or work assistance;
                            ``(vi) requests funding for drug treatment 
                        activities that do not adequately support and 
                        enhance Federal drug treatment programs and 
                        capacity, as determined by the Director;
                            ``(vii) requests funding for fiscal year 
                        2007 for activities of the Department of 
                        Education, unless it is accompanied by a report 
                        setting forth a plan for providing expedited 
                        consideration of student loan applications for 
                        all individuals who submitted an application 
                        for any Federal grant, loan, or work assistance 
                        that was rejected or denied pursuant to 
                        484(r)(1) of the Higher Education Act of 1965 
                        (20 U.S.C. 1091(r)(1)) by reason of a 
                        conviction for a drug-related offense not 
                        occurring during a period of enrollment for 
                        which the individual was receiving any Federal 
                        grant, loan, or work assistance; and
                            ``(viii) requests funding for the 
                        operations and management of the Department of 
                        Homeland Security that does not include a 
                        specific request for funds for the Office of 
                        Counternarcotics Enforcement to carry out its 
                        responsibilities under section 878 of the 
                        Homeland Security Act of 2002 (6 U.S.C. 
                        458).'';
            (3) in subparagraph (D)(iii), as so redesignated, by 
        inserting ``and the appropriate congressional committees'' 
        after ``House of Representatives''; and
            (4) in subparagraph (E)(ii)(II)(bb), as so redesignated, by 
        inserting ``and the appropriate congressional committees'' 
        after ``House of Representatives''.
    (f) Reprogramming and Transfer Requests.--Section 704(c)(4)(A) (21 
U.S.C. 1703(c)(4)(A)) is amended by striking ``$5,000,000'' and 
inserting ``$1,000,000''.
    (g) Powers of Director.--Section 704(d) (21 U.S.C. 1703(d)) is 
amended--
            (1) in paragraph (8)(D), by striking ``have been authorized 
        by Congress;'' and inserting ``authorized by law;'';
            (2) in paragraph (9)--
                    (A) by inserting ``notwithstanding any other 
                provision of law,'' after ``(9)''; and
                    (B) by striking ``Strategy; and'' and inserting 
                ``Strategy and notify the appropriate congressional 
                committees of any fund control notice issued;'';
            (3) in paragraph (10), by striking ``(22 U.S.C. 2291j).'' 
        and inserting ``(22 U.S.C. 2291j) and section 706 of the 
        Foreign Relations Authorization Act, Fiscal Year 2003 (22 
        U.S.C. 2291j-1); and''; and
            (4) by adding at the end the following new paragraph:
            ``(11) not later than August 1 of each year, submit to the 
        President a report, and transmit copies of the report to the 
        Secretary of State and the appropriate congressional 
        committees, that--
                    ``(A) provides the Director's assessment of which 
                countries are major drug transit countries or major 
                illicit drug producing countries as defined in section 
                481(e) of the Foreign Assistance Act of 1961 (22 U.S.C. 
                2291(e));
                    ``(B) provides the Director's assessment of whether 
                each country identified under subparagraph (A) has 
                cooperated fully with the United States or has taken 
                adequate steps on its own to achieve full compliance 
                with the goals and objectives established by the United 
                Nations Convention Against Illicit Traffic in Narcotic 
                Drugs and Psychotropic Substances and otherwise has 
                assisted in reducing the supply of illicit drugs to the 
                United States; and
                    ``(C) provides the Director's assessment of whether 
                application of procedures set forth in section 490 of 
                the Foreign Assistance Act of 1961 (22 U.S.C. 2291j), 
                as provided in section 706 of the Foreign Relations 
                Authorization Act, Fiscal Year 2003 (22 U.S.C. 2291j-
                1), is warranted with respect to countries the Director 
                assesses have not cooperated fully.''.
    (g) Fund Control Notices.--Section 704(f) (21 U.S.C. 1703(f)) is 
amended by adding at the end the following:
            ``(4) Congressional notice.--A copy of each fund control 
        notice shall be transmitted to the appropriate congressional 
        committees.
            ``(5) Restrictions.--The Director shall not issue a fund 
        control notice to direct that all or part of an amount 
        appropriated to the National Drug Control Program agency 
        account be obligated, modified, or altered in any manner 
        contrary, in whole or in part, to a specific appropriation or 
        statute.''.
    (h) Technical Amendments.--Section 704 (21 U.S.C. 1703) is 
amended--
            (1) in subsection (g)--
                    (A) by striking ``National Foreign Intelligence 
                Program'' and inserting ``National Intelligence 
                Program''; and
                    (B) by inserting a comma before ``and Tactical''; 
                and
            (2) in subsection (h), by striking ``Director of Central 
        Intelligence'' and inserting ``Director of National 
        Intelligence or the Director of the Central Intelligence 
        Agency''.
    (i) Requirement for South American Heroin Strategy.--
            (1) In general.--Not later than 90 days after the date of 
        the enactment of this Act, the Director of National Drug 
        Control Policy shall submit to the Congress a comprehensive 
        strategy that addresses the increased threat from South 
        American heroin, and in particular Colombian heroin and the 
        emerging threat from opium poppy grown in Peru and often 
        intended for transit to Columbia for processing into heroin.
            (2) Contents.--The strategy shall include--
                    (A) opium eradication efforts to eliminate the 
                problem at the source to prevent heroin from entering 
                the stream of commerce;
                    (B) interdiction and precursor chemical controls;
                    (C) demand reduction and treatment;
                    (D) alternative development programs, including 
                direct assistance to regional governments to demobilize 
                and provide alternative livelihoods to former members 
                of insurgent or other groups engaged in heroin, coca, 
                or other illicit drug production or trafficking;
                    (E) efforts to inform and involve local citizens in 
                the programs described in subparagraphs (A) through 
                (D), such as through leaflets advertising rewards for 
                information;
                    (F) provisions that ensure the maintenance at 
                current levels of efforts to eradicate coca in 
                Colombia; and
                    (G) assessment of the specific level of funding and 
                resources necessary to simultaneously address the 
                threat from South American heroin and the threat from 
                Colombian and Peruvian coca.
            (3) Treatment of classified or law enforcement sensitive 
        information.--Any content of the strategy that involves 
        information classified under criteria established by an 
        Executive order, or whose public disclosure, as determined by 
        the Director or the head of any relevant Federal agency, would 
        be detrimental to the law enforcement or national security 
        activities of any Federal, foreign, or international agency, 
        shall be presented to Congress separately from the rest of the 
        strategy.
    (j) Requirement for Afghan Heroin Strategy.--
            (1) In general.--Not later than 90 days after the date of 
        the enactment of this Act, the Director of the Office of 
        National Drug Control Policy shall submit to the Congress a 
        comprehensive strategy that addresses the increased threat from 
        Afghan heroin.
            (2) Contents.--The strategy shall include--
                    (A) opium crop eradication efforts to eliminate the 
                problem at the source to prevent heroin from entering 
                the stream of commerce;
                    (B) destruction or other direct elimination of 
                stockpiles of heroin and raw opium, and heroin 
                production and storage facilities;
                    (C) interdiction and precursor chemical controls;
                    (D) demand reduction and treatment;
                    (E) alternative development programs;
                    (F) measures to improve cooperation and 
                coordination between Federal Government agencies, and 
                between such agencies, agencies of foreign governments, 
                and international organizations with responsibility for 
                the prevention of heroin production in, or trafficking 
                out of, Afghanistan; and
                    (G) an assessment of the specific level of funding 
                and resources necessary significantly to reduce the 
                production and trafficking of heroin.
            (3) Treatment of classified or law enforcement sensitive 
        information.--Any content of the strategy that involves 
        information classified under criteria established by an 
        Executive order, or whose public disclosure, as determined by 
        the Director or the head of any relevant Federal agency, would 
        be detrimental to the law enforcement or national security 
        activities of any Federal, foreign, or international agency, 
        shall be presented to Congress separately from the rest of the 
        strategy.
    (k) Requirement for General Counterdrug Intelligence Plan.--
            (1) In general.--Not later than 120 days after the date of 
        enactment of this Act, and not later than every two years 
        thereafter, the Director of the Office of National Drug Control 
        Policy, with the concurrence of the Director of National 
        Intelligence, shall submit to the appropriate congressional 
        committees, a general counterdrug intelligence plan to improve 
        coordination, and eliminate unnecessary duplication, among the 
        counterdrug intelligence centers and information sharing 
        systems, and counterdrug activities of the Federal Government, 
        including the centers, systems, and activities of the following 
        departments and agencies:
                    (A) The Department of Defense, including the 
                Defense Intelligence Agency, and the joint interagency 
                task forces.
                    (B) The Department of the Treasury, including the 
                Financial Crimes Enforcement Network (FinCEN).
                    (C) The Central Intelligence Agency.
                    (D) The National Security Agency.
                    (E) The Department of Homeland Security, including 
                the United States Coast Guard, the bureau of Customs 
                and Border Protection, and the bureau of Immigration 
                and Customs Enforcement.
                    (F) The Department of Justice, including the 
                National Drug Intelligence Center (NDIC); the Drug 
                Enforcement Administration, including the El Paso 
                Intelligence Center (EPIC); the Federal Bureau of 
                Investigation; the Organized Crime Drug Enforcement 
                Task Force; and the Regional Information Sharing 
                System.
                    (G) The Office of National Drug Control Policy, 
                including the High Intensity Drug Trafficking Areas 
                Program.
                    (H) The Counterdrug Intelligence Executive 
                Secretariat.
            (2) Purpose.--The purpose of the plan under paragraph (1) 
        is to maximize the effectiveness of the centers and activities 
        referred to in that paragraph in achieving the objectives of 
        the National Drug Control Strategy promulgated under 21 U.S.C. 
        1705. In order to maximize such effectiveness, the plan shall--
                    (A) articulate clear and specific mission 
                statements (including purpose and scope of activity) 
                for each counterdrug intelligence center, system, and 
                activity, including the manner in which responsibility 
                for counterdrug intelligence activities will be 
                allocated among the counterdrug intelligence centers 
                and systems;
                    (B) specify each government agency (whether 
                Federal, State, or local) that participates in each 
                such center, system, and activity, including a 
                description of the extent and nature of that 
                participation;
                    (C) specify the relationship between such centers, 
                systems, and activities;
                    (D) specify the means by which proper oversight of 
                such centers, systems, and activities will be assured;
                    (E) specify the means by which counterdrug 
                intelligence and information will be forwarded 
                effectively to all levels of officials responsible for 
                United States counterdrug policy; and
                    (F) specify mechanisms to ensure that State and 
                local law enforcement agencies are apprised of 
                counterdrug intelligence and information acquired by 
                Federal law enforcement agencies in a manner which--
                            (i) facilitates effective counterdrug 
                        activities by State and local law enforcement 
                        agencies; and
                            (ii) provides such State and local law 
                        enforcement agencies with the information 
                        relating to the safety of officials involved in 
                        their counterdrug activities.
            (3) Definitions.--As used in this subsection--
                    (A) the term ``center'' refers to any center, 
                office, task force, or other coordinating organization 
                engaged in counterdrug intelligence or information 
                analyzing or sharing activities;
                    (B) the term ``system'' refers to any computerized 
                database or other electronic system used for 
                counterdrug intelligence or information analyzing or 
                sharing activities; and
                    (C) the term ``appropriate congressional 
                committees'' means the following:
                            (i) The Committee on Appropriations, the 
                        Committee on Foreign Relations, the Committee 
                        on the Judiciary, the Committee on Homeland 
                        Security and Governmental Affairs, the Caucus 
                        on International Narcotics Control, and the 
                        Select Committee on Intelligence of the Senate.
                            (ii) The Committee on Appropriations, the 
                        Committee on International Relations, the 
                        Committee on the Judiciary, the Committee on 
                        Government Reform, the Committee on Homeland 
                        Security, and the Permanent Select Committee on 
                        Intelligence of the House of Representatives.
            (4) Limitation.--The general counterdrug intelligence plan 
        shall not--
                    (A) change existing agency authorities or the laws 
                governing interagency relationships, but may include 
                recommendations about changes to such authorities or 
                laws; or
                    (B) include any information about specific methods 
                of obtaining, or sources of, intelligence or 
                information, or any information about specific 
                individuals, cases, investigations, or operations.
            (5) Classified or law enforcement sensitive information.--
        Any content of the general counterdrug intelligence plan that 
        involves information classified under criteria established by 
        an Executive order, or whose public disclosure, as determined 
        by the Director of the Office of National Drug Control Policy, 
        the Director of National Intelligence, or the head of any 
        Federal Government agency whose activities are described in the 
        plan, would be detrimental to the law enforcement or national 
        security activities of any Federal, State, or local agency, 
        shall be presented to Congress separately from the rest of the 
        report.
    (l) Requirement for Southwest Border Counternarcotics Strategy.--
            (1) In general.--Not later than 120 days after the date of 
        enactment of this Act, and every two years thereafter, the 
        Director of National Drug Control Policy shall submit to the 
        Congress a Southwest Border Counternarcotics Strategy.
            (2) Purposes.--The Southwest Border Counternarcotics 
        Strategy shall--
                    (A) set forth the Government's strategy for 
                preventing the illegal trafficking of drugs across the 
                international border between the United States and 
                Mexico, including through ports of entry and between 
                ports of entry on that border;
                    (B) state the specific roles and responsibilities 
                of the relevant National Drug Control Program agencies 
                (as defined in section 702 of the Office of National 
                Drug Control Policy Reauthorization Act of 1998 (21 
                U.S.C. 1701)) for implementing that strategy; and
                    (C) identify the specific resources required to 
                enable the relevant National Drug Control Program 
                agencies to implement that strategy.
            (3) Consultation with other agencies.--The Director shall 
        issue the Southwest Border Counternarcotics Strategy in 
        consultation with the heads of the relevant National Drug 
        Control Program agencies.
            (4) Limitation.--The Southwest Border Counternarcotics 
        Strategy shall not change existing agency authorities or the 
        laws governing interagency relationships, but may include 
        recommendations about changes to such authorities or laws.
            (5) Report to congress.--The Director shall provide a copy 
        of the Southwest Border Counternarcotics Strategy to the 
        appropriate congressional committees (as defined in section 702 
        of the Office of National Drug Control Policy Reauthorization 
        Act of 1998 (21 U.S.C. 1701)), and to the Committee on Armed 
        Services and the Committee on Homeland Security of the House of 
        Representatives, and the Committee on Homeland Security and 
        Governmental Affairs and the Committee on Armed Services of the 
        Senate.
            (6) Treatment of classified or law enforcement sensitive 
        information.--Any content of the Southwest Border 
        Counternarcotics Strategy that involves information classified 
        under criteria established by an Executive order, or whose 
        public disclosure, as determined by the Director or the head of 
        any relevant National Drug Control Program agency, would be 
        detrimental to the law enforcement or national security 
        activities of any Federal, State, or local agency, shall be 
        presented to Congress separately from the rest of the strategy.
    (m) Requirement for Scientific Study of Mycoherbicide in Illicit 
Drug Crop Eradication.--Not later than 90 days after the date of 
enactment of this Act, the Director of the Office of National Drug 
Control Policy shall submit to the Congress a report that includes a 
plan to conduct, on an expedited basis, a scientific study of the use 
of mycoherbicide as a means of illicit drug crop elimination by an 
appropriate Government scientific research entity, including a complete 
and thorough scientific peer review. The study shall include an 
evaluation of the likely human health and environmental impacts of such 
use. The report shall also include a plan to conduct controlled 
scientific testing in a major drug producing nation of mycoherbicide 
naturally existing in the producing nation.

SEC. 7. AMENDMENTS RELATING TO COORDINATION WITH OTHER AGENCIES.

    Section 705 (21 U.S.C. 1704) is amended--
            (1) in subsection (a)(1)(A), by striking ``abuse'';
            (2) in subsection (a)(2)(A), by striking ``Director of 
        Central Intelligence'' and inserting ``Director of National 
        Intelligence'';
            (3) in subsection (a)(2)(B), by striking ``Director of 
        Central Intelligence'' and inserting ``Director of National 
        Intelligence and the Director of the Central Intelligence 
        Agency'';
            (4) by amending paragraph (3) of subsection (a) to read as 
        follows:
            ``(3) Required reports.--
                    ``(A) Secretaries of the interior and 
                agriculture.--The Secretaries of Agriculture and 
                Interior shall, by July 1 of each year, jointly submit 
                to the Director, the appropriate congressional 
                committees, the Committee on Agriculture and the 
                Committee on Resources of the House of Representatives, 
                and the Committee on Agriculture and the Committee on 
                Energy and Natural Resources of the Senate, an 
                assessment of the quantity of illegal drug cultivation 
                and manufacturing in the United States on lands owned 
                or under the jurisdiction of the Federal Government for 
                the preceding year.
                    ``(B) Attorney general.--The Attorney General 
                shall, by July 1 of each year, submit to the Director 
                and the appropriate congressional committees 
                information for the preceding year regarding the number 
                and type of--
                            ``(i) arrests for drug violations;
                            ``(ii) prosecutions for drug violations by 
                        United States Attorneys; and
                            ``(iii) seizures of drugs by each component 
                        of the Department of Justice seizing drugs, as 
                        well as statistical information on the 
                        geographic areas of such seizures.
                    ``(C) Secretary of homeland security.--The 
                Secretary of Homeland Security shall, by July 1 of each 
                year, submit to the Director, the appropriate 
                congressional committees, and the Committee on Homeland 
                Security of the House of Representatives, and the 
                Committee on Homeland Security and Governmental Affairs 
                of the Senate, information for the preceding year 
                regarding--
                            ``(i) the number and type of seizures of 
                        drugs by each component of the Department of 
                        Homeland Security seizing drugs, as well as 
                        statistical information on the geographic areas 
                        of such seizures; and
                            ``(ii) the number of air and maritime 
                        patrol hours undertaken by each component of 
                        that Department primarily dedicated to drug 
                        supply reduction missions.
                    ``(D) Secretary of defense.--The Secretary of 
                Defense shall, by July 1 of each year, submit to the 
                Director, the appropriate congressional committees, the 
                Committee on Armed Services of the House of 
                Representatives, and the Committee on Armed Services of 
                the Senate, information for the preceding year 
                regarding the number of air and maritime patrol hours 
                primarily dedicated to drug supply reduction missions 
                undertaken by each component of the Department of 
                Defense.'';
            (5) in subsection (b)(2)(B), by striking ``Program.'' and 
        inserting ``Strategy.''; and
            (6) in subsection (c), by striking ``in'' and inserting 
        ``on''.

SEC. 8. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, AND ASSESSMENT OF 
              NATIONAL DRUG CONTROL STRATEGY.

    Section 706 (21 U.S.C. 1705) is amended to read as follows:

``SEC. 706. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, AND ASSESSMENT OF 
              NATIONAL DRUG CONTROL STRATEGY.

    ``(a) Timing, Contents, and Process for Development and Submission 
of National Drug Control Strategy.--
            ``(1) In general.--Not later than February 1 of each year, 
        the President shall submit to Congress a National Drug Control 
        Strategy, which shall set forth a comprehensive plan for 
        reducing illicit drug use and the consequences of illicit drug 
        use in the United States by reducing the demand for illegal 
        drugs, limiting the availability of illegal drugs, and 
        conducting law enforcement activities with respect to illegal 
        drugs.
            ``(2) Contents.--
                    ``(A) In general.--The National Drug Control 
                Strategy submitted under paragraph (1) shall include 
                the following:
                            ``(i) Comprehensive, research-based, long-
                        range, and quantifiable goals for reducing 
                        illicit drug use and the consequences of 
                        illicit drug use in the United States.
                            ``(ii) Annual quantifiable objectives for 
                        demand reduction, supply reduction, and law 
                        enforcement activities, specific targets to 
                        accomplish long-range quantifiable reduction in 
                        illicit drug use as determined by the Director, 
                        and specific measurements to evaluate progress 
                        toward the targets and strategic goals.
                            ``(iii) A strategy to reduce the 
                        availability and purity of illegal drugs and 
                        the level of drug-related crime in the United 
                        States.
                            ``(iv) An assessment of Federal 
                        effectiveness in achieving the National Drug 
                        Control Strategy for the previous year, 
                        including a specific evaluation of whether the 
                        objectives and targets for reducing illicit 
                        drug use for the previous year were met and 
                        reasons for the success or failure of the 
                        previous year's Strategy.
                            ``(v) A general review of the status of, 
                        and trends in, international, State, and local 
                        drug control activities to ensure that the 
                        United States pursues well-coordinated and 
                        effective drug control at all levels of 
                        government.
                            ``(vi) A general review of the status of, 
                        and trends in, demand reduction activities by 
                        private sector entities and community-based 
                        organizations, including faith-based 
                        organizations, to determine their effectiveness 
                        and the extent of cooperation, coordination, 
                        and mutual support between such entities and 
                        organizations and Federal, State, and local 
                        government agencies.
                            ``(vii) An assessment of current illicit 
                        drug use (including inhalants and steroids) and 
                        availability, impact of illicit drug use, and 
                        treatment availability, which assessment shall 
                        include--
                                    ``(I) estimates of drug prevalence 
                                and frequency of use as measured by 
                                national, State, and local surveys of 
                                illicit drug use and by other special 
                                studies of nondependent and dependent 
                                illicit drug use;
                                    ``(II) illicit drug use in the 
                                workplace and the productivity lost by 
                                such use; and
                                    ``(III) illicit drug use by 
                                arrestees, probationers, and parolees.
                            ``(viii) An assessment of the reduction of 
                        illicit drug availability, as measured by--
                                    ``(I) the quantities of cocaine, 
                                heroin, marijuana, methamphetamine, 
                                ecstasy, and other drugs available for 
                                consumption in the United States;
                                    ``(II) the amount of marijuana, 
                                cocaine, heroin, methamphetamine, 
                                ecstasy, and precursor chemicals and 
                                other drugs entering the United States;
                                    ``(III) the number of illicit drug 
                                manufacturing laboratories seized and 
                                destroyed and the number of hectares of 
                                marijuana, poppy, and coca cultivated 
                                and destroyed domestically and in other 
                                countries;
                                    ``(IV) the number of metric tons of 
                                marijuana, heroin, cocaine, and 
                                methamphetamine seized and other drugs; 
                                and
                                    ``(V) changes in the price and 
                                purity of heroin, methamphetamine, and 
                                cocaine, changes in the price of 
                                ecstasy, and changes in 
                                tetrahydrocannabinol level of marijuana 
                                and other drugs.
                            ``(ix) An assessment of the reduction of 
                        the consequences of illicit drug use and 
                        availability, which shall include--
                                    ``(I) the burden illicit drug users 
                                place on hospital emergency departments 
                                in the United States, such as the 
                                quantity of illicit drug-related 
                                services provided;
                                    ``(II) the annual national health 
                                care cost of illicit drug use; and
                                    ``(III) the extent of illicit drug-
                                related crime and criminal activity.
                            ``(x) A general review of the status of, 
                        and trends in, of drug treatment in the United 
                        States, by assessing--
                                    ``(I) public and private treatment 
                                utilization; and
                                    ``(II) the number of illicit drug 
                                users the Director estimates meet 
                                diagnostic criteria for treatment.
                            ``(xi) A review of the research agenda of 
                        the Counterdrug Technology Assessment Center to 
                        reduce the availability and abuse of drugs.
                            ``(xii) A summary of the efforts made by 
                        Federal agencies to coordinate with private 
                        sector entities to conduct private research and 
                        development of medications to treat addiction 
                        by--
                                    ``(I) screening chemicals for 
                                potential therapeutic value;
                                    ``(II) developing promising 
                                compounds;
                                    ``(III) conducting clinical trials;
                                    ``(IV) seeking, where appropriate, 
                                Food and Drug Administration approval 
                                for drugs to treat addiction;
                                    ``(V) marketing, where appropriate, 
                                the drug for the treatment of 
                                addiction;
                                    ``(VI) urging physicians, where 
                                appropriate, to use the drug in the 
                                treatment of addiction; and
                                    ``(VII) encouraging, where 
                                appropriate, insurance companies to 
                                reimburse the cost of the drug for the 
                                treatment of addiction.
                            ``(xiii) Such additional statistical data 
                        and information as the Director considers 
                        appropriate to demonstrate and assess trends 
                        relating to illicit drug use, the effects and 
                        consequences of illicit drug use, supply 
                        reduction, demand reduction, drug-related law 
                        enforcement, and the implementation of the 
                        National Drug Control Strategy.
                            ``(xiv) A supplement reviewing the 
                        activities of each individual National Drug 
                        Control Program agency during the previous year 
                        with respect to the National Drug Control 
                        Strategy and the Director's assessment of the 
                        progress of each National Drug Control Program 
                        agency in meeting its responsibilities under 
                        the National Drug Control Strategy.
                    ``(B) Classified information.--Any contents of the 
                National Drug Control Strategy that involve information 
                properly classified under criteria established by an 
                Executive order shall be presented to Congress 
                separately from the rest of the National Drug Control 
                Strategy.
                    ``(C) Selection of data and information.--In 
                selecting data and information for inclusion under 
                subparagraph (A), the Director shall ensure--
                            ``(i) the inclusion of data and information 
                        that will permit analysis of current trends 
                        against previously compiled data and 
                        information where the Director believes such 
                        analysis enhances long-term assessment of the 
                        National Drug Control Strategy; and
                            ``(ii) the inclusion of data and 
                        information to permit a standardized and 
                        uniform assessment of the effectiveness of drug 
                        treatment programs in the United States.
            ``(3) Process for development and submission.--
                    ``(A) Consultation.--In developing and effectively 
                implementing the National Drug Control Strategy, the 
                Director--
                            ``(i) shall consult with--
                                    ``(I) the heads of the National 
                                Drug Control Program agencies;
                                    ``(II) Congress;
                                    ``(III) State and local officials;
                                    ``(IV) private citizens and 
                                organizations, including community- and 
                                faith-based organizations, with 
                                experience and expertise in demand 
                                reduction;
                                    ``(V) private citizens and 
                                organizations with experience and 
                                expertise in supply reduction;
                                    ``(VI) private citizens and 
                                organizations with experience and 
                                expertise in law enforcement; and
                                    ``(VII) appropriate representatives 
                                of foreign governments;
                            ``(ii) with the concurrence of the Attorney 
                        General, may require the El Paso Intelligence 
                        Center to undertake specific tasks or projects 
                        to implement the National Drug Control 
                        Strategy;
                            ``(iii) with the concurrence of the 
                        Director of National Intelligence and the 
                        Attorney General, may request that the National 
                        Drug Intelligence Center undertake specific 
                        tasks or projects to implement the National 
                        Drug Control Strategy; and
                            ``(iv) may make recommendations to the 
                        Secretary of Health and Human Services on 
                        research that supports or advances the National 
                        Drug Control Strategy.
                    ``(B) Commitment to support strategy.--In 
                satisfying the requirements of subparagraph (A)(i), the 
                Director shall ensure, to the maximum extent possible, 
                that State and local officials and relevant private 
                organizations commit to support and take steps to 
                achieve the goals and objectives of the National Drug 
                Control Strategy.
                    ``(C) Recommendations.--Recommendations under 
                subparagraph (A)(iv) may include recommendations of 
                research to be performed at the National Institutes of 
                Health, including the National Institute on Drug Abuse, 
                or any other appropriate agency within the Department 
                of Health and Human Services.
                    ``(D) Inclusion in strategy.--The National Drug 
                Control Strategy under this subsection shall include a 
                list of each entity consulted under subparagraph 
                (A)(i).
            ``(4) Submission of revised strategy.--The President may 
        submit to Congress a revised National Drug Control Strategy 
        that meets the requirements of this section--
                    ``(A) at any time, upon a determination by the 
                President, in consultation with the Director, that the 
                National Drug Control Strategy in effect is not 
                sufficiently effective; or
                    ``(B) if a new President or Director takes office.
    ``(b) Performance Measurement System.--Not later than February 1 of 
each year, the Director shall submit to Congress, as part of the 
National Drug Control Strategy, a description of a national drug 
control performance measurement system that--
            ``(1) develops 2-year and 5-year performance measures and 
        targets for each National Drug Control Strategy goal and 
        objective established for reducing drug use, drug availability, 
        and the consequences of drug use;
            ``(2) describes the sources of information and data that 
        will be used for each performance measure incorporated into the 
        performance measurement system;
            ``(3) identifies major programs and activities of the 
        National Drug Control Program agencies that support the goals 
        and annual objectives of the National Drug Control Strategy;
            ``(4) evaluates the contribution of demand reduction and 
        supply reduction activities implemented by each National Drug 
        Control Program agency in support of the National Drug Control 
        Strategy;
            ``(5) monitors consistency of drug-related goals and 
        objectives among the National Drug Control Program agencies and 
        ensures that each agency's goals, objectives, and budgets 
        support and are fully consistent with the National Drug Control 
        Strategy; and
            ``(6) coordinates the development and implementation of 
        national drug control data collection and reporting systems to 
        support policy formulation and performance measurement, 
        including an assessment of--
                    ``(A) the quality of current drug use measurement 
                instruments and techniques to measure supply reduction 
                and demand reduction activities;
                    ``(B) the adequacy of the coverage of existing 
                national drug use measurement instruments and 
                techniques to measure the illicit drug user population, 
                and groups that are at risk for illicit drug use; and
                    ``(C) the adequacy of the coverage of existing 
                national treatment outcome monitoring systems to 
                measure the effectiveness of drug abuse treatment in 
                reducing illicit drug use and criminal behavior during 
                and after the completion of substance abuse treatment; 
                and
            ``(7) identifies the actions the Director shall take to 
        correct any inadequacies, deficiencies, or limitations 
        identified in the assessment described in paragraph (6).
    ``(c) Modifications.--A description of any modifications made 
during the preceding year to the national drug performance measurement 
system described in subsection (b) shall be included in each report 
submitted under subsection (a).''.

SEC. 9. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.

    Section 707 (21 U.S.C. 1706) is amended to read as follows:

``SEC. 707. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.

    ``(a) Establishment.--
            ``(1) In general.--There is established in the Office a 
        program to be known as the High Intensity Drug Trafficking 
        Areas Program (in this section referred to as the `Program').
            ``(2) Purpose.--The purpose of the Program is to reduce 
        drug trafficking and drug production in the United States by--
                    ``(A) facilitating cooperation among Federal, 
                State, and local law enforcement agencies to share 
                information and implement coordinated enforcement 
                activities;
                    ``(B) enhancing intelligence sharing among Federal, 
                State, and local law enforcement agencies;
                    ``(C) providing reliable intelligence to law 
                enforcement agencies needed to design effective 
                enforcement strategies and operations; and
                    ``(D) supporting coordinated law enforcement 
                strategies which maximize use of available resources to 
                reduce the supply of illegal drugs in designated areas 
                and in the United States as a whole.
    ``(b) Designation.--The Director, upon consultation with the 
Attorney General, the Secretary of the Treasury, the Secretary of 
Homeland Security, heads of the National Drug Control Program agencies, 
and the Governor of each applicable State, may designate any specified 
area of the United States as a high intensity drug trafficking area. 
After making such a designation and in order to provide Federal 
assistance to the area so designated, the Director may--
            ``(1) obligate such sums as are appropriated for the 
        Program;
            ``(2) direct the temporary reassignment of Federal 
        personnel to such area, subject to the approval of the head of 
        the department or agency that employs such personnel;
            ``(3) take any other action authorized under section 704 to 
        provide increased Federal assistance to those areas; and
            ``(4) coordinate activities under this section 
        (specifically administrative, recordkeeping, and funds 
        management activities) with State and local officials.
    ``(c) Petitions for Designation.--The Director shall establish 
regulations under which a coalition of interested law enforcement 
agencies from an area may petition for designation as a high intensity 
drug trafficking area. Such regulations shall provide for a regular 
review by the Director of the petition, including a recommendation 
regarding the merit of the petition to the Director by a panel of 
qualified, independent experts.
    ``(d) Factors for Consideration.--In considering whether to 
designate an area under this section as a high intensity drug 
trafficking area, the Director shall consider, in addition to such 
other criteria as the Director considers to be appropriate, the extent 
to which--
            ``(1) the area is a significant center of illegal drug 
        production, manufacturing, importation, or distribution;
            ``(2) State and local law enforcement agencies have 
        committed resources to respond to the drug trafficking problem 
        in the area, thereby indicating a determination to respond 
        aggressively to the problem;
            ``(3) drug-related activities in the area are having a 
        significant harmful impact in the area, and in other areas of 
        the country; and
            ``(4) a significant increase in allocation of Federal 
        resources is necessary to respond adequately to drug-related 
        activities in the area.
    ``(e) Organization of High Intensity Drug Trafficking Areas.--
            ``(1) Executive board and officers.--To be eligible for 
        funds appropriated under this section, each high intensity drug 
        trafficking area shall be governed by an Executive Board. The 
        Executive Board shall designate a chairman, vice chairman, and 
        any other officers to the Executive Board that it determines 
        are necessary.
            ``(2) Responsibilities.--The Executive Board of a high 
        intensity drug trafficking area shall be responsible for--
                    ``(A) providing direction and oversight in 
                establishing and achieving the goals of the high 
                intensity drug trafficking area;
                    ``(B) managing the funds of the high intensity drug 
                trafficking area;
                    ``(C) reviewing and approving all funding proposals 
                consistent with the overall objective of the high 
                intensity drug trafficking area; and
                    ``(D) reviewing and approving all reports to the 
                Director on the activities of the high intensity drug 
                trafficking area.
            ``(3) Board representation.--None of the funds appropriated 
        under this section may be expended for any high intensity drug 
        trafficking area, or for a partnership or region of a high 
        intensity drug trafficking area, if that area's, region's or 
        partnership's Executive Board does not apportion an equal 
        number of votes between representatives of participating 
        Federal agencies and representatives of participating State and 
        local agencies. Where it is impractical for a equal number of 
        representatives of Federal agencies and State and local 
        agencies to attend a meeting of an Executive Board in person, 
        the Executive Board may use a system of proxy votes or weighted 
        votes to achieve the voting balance required by this paragraph.
            ``(4) No agency relationship.--The eligibility requirements 
        of this section are intended to ensure the responsible use of 
        Federal funds. Nothing in this section is intended to create an 
        agency relationship between individual high intensity drug 
        trafficking areas and the Federal Government.
    ``(f) Use of Funds.--The Director shall ensure that no Federal 
funds appropriated for the Program are expended for the establishment 
or expansion of drug treatment programs, and shall ensure that not more 
than five percent of the Federal funds appropriated for the Program are 
expended for the establishment of drug prevention programs.
    ``(g) Counterterrorism Activities.--
            ``(1) Assistance authorized.--The Director may authorize 
        use of resources available for the Program to assist Federal, 
        State, and local law enforcement agencies in investigations and 
        activities related to terrorism and prevention of terrorism, 
        especially but not exclusively with respect to such 
        investigations and activities that are also related to drug 
        trafficking.
            ``(2) Limitation.--The Director shall ensure--
                    ``(A) that assistance provided under paragraph (1) 
                remains incidental to the purpose of the Program to 
                reduce drug availability and carry out drug-related law 
                enforcement activities; and
                    ``(B) that significant resources of the Program are 
                not redirected to activities exclusively related to 
                terrorism, except on a temporary basis under 
                extraordinary circumstances, as determined by the 
                Director.
    ``(h) Role of Drug Enforcement Administration.--The Director, in 
consultation with the Attorney General, shall ensure that a 
representative of the Drug Enforcement Administration is included in 
the Intelligence Support Center for each high intensity drug 
trafficking area.
    ``(i) Annual HIDTA Program Budget Submissions.--As part of the 
documentation that supports the President's annual budget request for 
the Office, the Director shall submit to Congress a budget 
justification that includes the following:
            ``(1) The amount requested for each high intensity drug 
        trafficking area with supporting narrative descriptions and 
        rationale for each request.
            ``(2) A detailed justification for each funding request 
        that explains the reasons for the requested funding level, how 
        such funding level was determined based on a current assessment 
        of the drug trafficking threat in each high intensity drug 
        trafficking area, how such funding will ensure that the goals 
        and objectives of each such area will be achieved, and how such 
        funding supports the National Drug Control Strategy.
    ``(j) Emerging Threat Response Fund.--
            ``(1) In general.--The Director may expend up to 10 percent 
        of the amounts appropriated under this section on a 
        discretionary basis, to respond to any emerging drug 
        trafficking threat in an existing high intensity drug 
        trafficking area, or to establish a new high intensity drug 
        trafficking area or expand an existing high intensity drug 
        trafficking area, in accordance with the criteria established 
        under paragraph (2).
            ``(2) Consideration of impact.--In allocating funds under 
        this subsection, the Director shall consider--
                    ``(A) the impact of activities funded on reducing 
                overall drug traffic in the United States, or 
                minimizing the probability that an emerging drug 
                trafficking threat will spread to other areas of the 
                United States; and
                    ``(B) such other criteria as the Director considers 
                appropriate.
    ``(k) Evaluation.--
            ``(1) Initial report.--Not later than 90 days after the 
        date of the enactment of this subsection, the Director shall, 
        after consulting with the Executive Boards of each designated 
        high intensity drug trafficking area, submit a report to 
        Congress that describes, for each designated high intensity 
        drug trafficking area--
                    ``(A) the specific purposes for the high intensity 
                drug trafficking area;
                    ``(B) the specific long-term and short-term goals 
                and objectives for the high intensity drug trafficking 
                area;
                    ``(C) the measurements that will be used to 
                evaluate the performance of the high intensity drug 
                trafficking area in achieving the long-term and short-
                term goals; and
                    ``(D) the reporting requirements needed to evaluate 
                the performance of the high intensity drug trafficking 
                area in achieving the long-term and short-term goals.
            ``(2) Evaluation of hidta program as part of national drug 
        control strategy.--For each designated high intensity drug 
        trafficking area, the Director shall submit, as part of the 
        annual National Drug Control Strategy report, a report that--
                    ``(A) describes--
                            ``(i) the specific purposes for the high 
                        intensity drug trafficking area; and
                            ``(ii) the specific long-term and short-
                        term goals and objectives for the high 
                        intensity drug trafficking area; and
                    ``(B) includes an evaluation of the performance of 
                the high intensity drug trafficking area in 
                accomplishing the specific long-term and short-term 
                goals and objectives identified under paragraph (1)(B).
    ``(l) Assessment of Drug Enforcement Task Forces in High Intensity 
Drug Trafficking Areas.--Not later than 180 days after the date of 
enactment of this subsection, and as part of each subsequent annual 
National Drug Control Strategy report, the Director shall submit to 
Congress a report--
            ``(1) assessing the number and operation of all federally 
        funded drug enforcement task forces within each high intensity 
        drug trafficking area; and
            ``(2) describing--
                    ``(A) each Federal, State, and local drug 
                enforcement task force operating in the high intensity 
                drug trafficking area;
                    ``(B) how such task forces coordinate with each 
                other, with any high intensity drug trafficking area 
                task force, and with investigations receiving funds 
                from the Organized Crime and Drug Enforcement Task 
                Force;
                    ``(C) what steps, if any, each such task force 
                takes to share information regarding drug trafficking 
                and drug production with other federally funded drug 
                enforcement task forces in the high intensity drug 
                trafficking area;
                    ``(D) the role of the high intensity drug 
                trafficking area in coordinating the sharing of such 
                information among task forces;
                    ``(E) the nature and extent of cooperation by each 
                Federal, State, and local participant in ensuring that 
                such information is shared among law enforcement 
                agencies and with the high intensity drug trafficking 
                area;
                    ``(F) the nature and extent to which information 
                sharing and enforcement activities are coordinated with 
                joint terrorism task forces in the high intensity drug 
                trafficking area; and
                    ``(G) any recommendations for measures needed to 
                ensure that task force resources are utilized 
                efficiently and effectively to reduce the availability 
                of illegal drugs in the high intensity drug trafficking 
                areas.
    ``(m) Assessment of Intelligence Sharing in High Intensity Drug 
Trafficking Areas--program.--Not later than 180 days after the date of 
the enactment of this subsection, and as part of each subsequent annual 
National Drug Control Strategy report, the Director shall submit to 
Congress a report--
            ``(1) evaluating existing and planned intelligence systems 
        supported by each high intensity drug trafficking area, or 
        utilized by task forces receiving any funding under the 
        Program, including the extent to which such systems ensure 
        access and availability of intelligence to Federal, State, and 
        local law enforcement agencies within the high intensity drug 
        trafficking area and outside of it;
            ``(2) the extent to which Federal, State, and local law 
        enforcement agencies participating in each high intensity drug 
        trafficking area are sharing intelligence information to assess 
        current drug trafficking threats and design appropriate 
        enforcement strategies; and
            ``(3) the measures needed to improve effective sharing of 
        information and intelligence regarding drug trafficking and 
        drug production among Federal, State, and local law enforcement 
        participating in a high intensity drug trafficking area, and 
        between such agencies and similar agencies outside the high 
        intensity drug trafficking area.
    ``(n) Coordination of Intelligence Sharing With Organized Crime 
Drug Enforcement Task Force Program.--The Director, in consultation 
with the Attorney General, shall ensure that any drug enforcement 
intelligence obtained by the Intelligence Support Center for each high 
intensity drug trafficking area is shared, on a timely basis, with the 
drug intelligence fusion center operated by the Organized Crime Drug 
Enforcement Task Force of the Department of Justice.
    ``(o) Use of Funds to Combat Methamphetamine Trafficking.--
            ``(1) In general.--
                    ``(A) Requirement.--The Director shall ensure that, 
                of the amounts appropriated for a fiscal year for the 
                Program, at least $15,000,000 is allocated to combat 
                the trafficking of methamphetamine in areas designated 
                by the Director as high intensity drug trafficking 
                areas.
                    ``(B) Activities.--In meeting the requirement in 
                subparagraph (A), the Director shall transfer funds to 
                appropriate Federal, State, and local governmental 
                agencies for employing additional Federal law 
                enforcement personnel, or facilitating the employment 
                of additional State and local law enforcement 
                personnel, including agents, investigators, 
                prosecutors, laboratory technicians, chemists, 
                investigative assistants, and drug prevention 
                specialists.
            ``(2) Apportionment of funds.--
                    ``(A) Factors in apportionment.--The Director shall 
                apportion amounts allocated under paragraph (1) among 
                areas designated by the Director as high intensity drug 
                trafficking areas based on the following factors:
                            ``(i) The number of methamphetamine 
                        manufacturing facilities discovered by Federal, 
                        State, or local law enforcement officials in 
                        the area during the previous fiscal year.
                            ``(ii) The number of methamphetamine 
                        prosecutions in Federal, State, or local courts 
                        in the area during the previous fiscal year.
                            ``(iii) The number of methamphetamine 
                        arrests by Federal, State, or local law 
                        enforcement officials in the area during the 
                        previous fiscal year.
                            ``(iv) The amounts of methamphetamine or 
                        listed chemicals (as that term is defined in 
                        section 102(33) of the Controlled Substances 
                        Act (21 U.S.C. 802(33)) seized by Federal, 
                        State, or local law enforcement officials in 
                        the area during the previous fiscal year.
                            ``(v) Intelligence and predictive data from 
                        the Drug Enforcement Administration showing 
                        patterns and trends in abuse, trafficking, and 
                        transportation in methamphetamine and listed 
                        chemicals (as that term is so defined).
                    ``(B) Certification.--Before the Director 
                apportions any funds under this paragraph to a high 
                intensity drug trafficking area, the Director shall 
                certify that the law enforcement entities responsible 
                for clandestine methamphetamine laboratory seizures in 
                that area are providing laboratory seizure data to the 
                national clandestine laboratory database at the El Paso 
                Intelligence Center.
    ``(p) Authorization of Appropriations.--There is authorized to be 
appropriated to the Office of National Drug Control Policy to carry out 
this section--
            ``(1) $280,000,000 for fiscal year 2007;
            ``(2) $290,000,000 for each of fiscal years 2008 and 2009; 
        and
            ``(3) $300,000,000 for each of fiscal years 2010 and 
        2011.''.

SEC. 10. FUNDING FOR CERTAIN HIGH INTENSITY DRUG TRAFFICKING AREAS.

    (a) Short Title.--This section may be cited as the ``Dawson Family 
Community Protection Act''.
    (b) Findings.--Congress finds the following:
            (1) In the early morning hours of October 16, 2002, the 
        home of Carnell and Angela Dawson was firebombed in apparent 
        retaliation for Mrs. Dawson's notification of police about 
        persistent drug distribution activity in their East Baltimore 
        City neighborhood.
            (2) The arson claimed the lives of Mr. and Mrs. Dawson and 
        their 5 young children, aged 9 to 14.
            (3) The horrific murder of the Dawson family is a stark 
        example of domestic narco-terrorism.
            (4) In all phases of counter-narcotics law enforcement--
        from prevention to investigation to prosecution to reentry--the 
        voluntary cooperation of ordinary citizens is a critical 
        component.
            (5) Voluntary cooperation is difficult for law enforcement 
        officials to obtain when citizens feel that cooperation carries 
        the risk of violent retaliation by illegal drug trafficking 
        organizations and their affiliates.
            (6) Public confidence that law enforcement is doing all it 
        can to make communities safe is a prerequisite for voluntary 
        cooperation among people who may be subject to intimidation or 
        reprisal (or both).
            (7) Witness protection programs are insufficient on their 
        own to provide security because many individuals and families 
        who strive every day to make distressed neighborhoods livable 
        for their children, other relatives, and neighbors will resist 
        or refuse offers of relocation by local, State, and Federal 
        prosecutorial agencies and because, moreover, the continued 
        presence of strong individuals and families is critical to 
        preserving and strengthening the social fabric in such 
        communities.
            (8) Where (as in certain sections of Baltimore City) 
        interstate trafficking of illegal drugs has severe ancillary 
        local consequences within areas designated as high intensity 
        drug trafficking areas, it is important that supplementary High 
        Intensity Drug Trafficking Areas Program funds be committed to 
        support initiatives aimed at making the affected communities 
        safe for the residents of those communities and encouraging 
        their cooperation with local, State, and Federal law 
        enforcement efforts to combat illegal drug trafficking.
    (c) Funding for Certain High Intensity Drug Trafficking Areas.--
Section 707 (21 U.S.C. 1706), as amended by section 9, is further 
amended by adding at the end the following new subsection:
    ``(q) Specific Purposes.--
            ``(1) In general.--The Director shall ensure that, of the 
        amounts appropriated for a fiscal year for the Program, at 
        least $7,000,000 is used in high intensity drug trafficking 
        areas with severe neighborhood safety and illegal drug 
        distribution problems.
            ``(2) Required uses.--The funds used under paragraph (1) 
        shall be used--
                    ``(A) to ensure the safety of neighborhoods and the 
                protection of communities, including the prevention of 
                the intimidation of potential witnesses of illegal drug 
                distribution and related activities; and
                    ``(B) to combat illegal drug trafficking through 
                such methods as the Director considers appropriate, 
                such as establishing or operating (or both) a toll-free 
                telephone hotline for use by the public to provide 
                information about illegal drug-related activities.''.

SEC. 11. AMENDMENTS RELATING TO COUNTER-DRUG TECHNOLOGY ASSESSMENT 
              CENTER.

    (a) Chief Scientist.--Section 708(b) (21 U.S.C. 1707(b)) is 
amended--
            (1) in the heading by striking ``Director of Technology.--
        '' and inserting ``Chief Scientist.--''; and
            (2) by striking ``Director of Technology,'' and inserting 
        ``Chief Scientist,''.
    (b) Additional Responsibilities of Director.--Section 708(c) (21 
U.S.C. 1707(c)) is amended to read as follows:
    ``(c) Additional Responsibilities of the Director of National Drug 
Control Policy.--
            ``(1) In general.--The Director, acting through the Chief 
        Scientist shall--
                    ``(A) identify and define the short-, medium-, and 
                long-term scientific and technological needs of 
                Federal, State, and local law enforcement agencies 
                relating to drug enforcement, including--
                            ``(i) advanced surveillance, tracking, and 
                        radar imaging;
                            ``(ii) electronic support measures;
                            ``(iii) communications;
                            ``(iv) data fusion, advanced computer 
                        systems, and artificial intelligence; and
                            ``(v) chemical, biological, radiological 
                        (including neutron, electron, and graviton), 
                        and other means of detection;
                    ``(B) identify demand reduction (including drug 
                prevention) basic and applied research needs and 
                initiatives, in consultation with affected National 
                Drug Control Program agencies, including--
                            ``(i) improving treatment through 
                        neuroscientific advances;
                            ``(ii) improving the transfer of biomedical 
                        research to the clinical setting; and
                            ``(iii) in consultation with the National 
                        Institute on Drug Abuse and the Substance Abuse 
                        and Mental Health Services Administration, and 
                        through interagency agreements or grants, 
                        examining addiction and rehabilitation research 
                        and the application of technology to expanding 
                        the effectiveness or availability of drug 
                        treatment;
                    ``(C) make a priority ranking of such needs 
                identified in subparagraphs (A) and (B) according to 
                fiscal and technological feasibility, as part of a 
                National Counterdrug Research and Development Program;
                    ``(D) oversee and coordinate counterdrug technology 
                initiatives with related activities of other Federal 
                civilian and military departments;
                    ``(E) provide support to the development and 
                implementation of the national drug control performance 
                measurement system established under subsection (b) of 
                section 706;
                    ``(F) with the advice and counsel of experts from 
                State and local law enforcement agencies, oversee and 
                coordinate a technology transfer program for the 
                transfer of technology to State and local law 
                enforcement agencies; and
                    ``(G) pursuant to the authority of the Director of 
                National Drug Control Policy under section 704, submit 
                requests to Congress for the reprogramming or transfer 
                of funds appropriated for counterdrug technology 
                research and development.
            ``(2) Priorities in transferring technology.--
                    ``(A) In general.--The Chief Scientist shall give 
                priority, in transferring technology under paragraph 
                (1)(F), based on the following criteria:
                            ``(i) the need of potential recipients for 
                        such technology;
                            ``(ii) the effectiveness of the technology 
                        to enhance current counterdrug activities of 
                        potential recipients; and
                            ``(iii) the ability and willingness of 
                        potential recipients to evaluate transferred 
                        technology.
                    ``(B) Interdiction and border drug law enforcement 
                technologies.--The Chief Scientist shall give priority, 
                in transferring technologies most likely to assist in 
                drug interdiction and border drug law enforcement, to 
                State, local, and tribal law enforcement agencies in 
                southwest border areas and northern border areas with 
                significant traffic in illicit drugs.
            ``(3) Limitation on authority.--The authority granted to 
        the Director under this subsection shall not extend to the 
        direct management of individual projects or other operational 
        activities.
            ``(4) Report.--On or before July 1 of each year, the 
        Director shall submit a report to the appropriate congressional 
        committees that addresses the following:
                    ``(A) The number of requests received during the 
                previous 12 months, including the identity of each 
                requesting agency and the type of technology requested.
                    ``(B) The number of requests fulfilled during the 
                previous 12 months, including the identity of each 
                recipient agency and the type of technology 
                transferred.
                    ``(C) A summary of the criteria used in making the 
                determination on what requests were funded and what 
                requests were not funded, except that such summary 
                shall not include specific information on any 
                individual requests.
                    ``(D) A general assessment of the future needs of 
                the program, based on expected changes in threats, 
                expected technologies, and likely need from potential 
                recipients.
                    ``(E) An assessment of the effectiveness of the 
                technologies transferred, based in part on the 
                evaluations provided by the recipients, with a 
                recommendation whether the technology should continue 
                to be offered through the program.''.
    (c) Assistance From Secretary of Homeland Security.--Section 708(d) 
(21 U.S.C. 1707(d)) is amended by inserting ``, the Secretary of 
Homeland Security,'' after ``The Secretary of Defense''.

SEC. 12. NATIONAL YOUTH ANTIDRUG MEDIA CAMPAIGN.

    (a) In General.--Section 709 (21 U.S.C. 1708) is amended to read as 
follows:

``SEC. 709. NATIONAL YOUTH ANTIDRUG MEDIA CAMPAIGN.

    ``(a) In General.--The Director shall conduct a national youth 
anti-drug media campaign (referred to in this subtitle as the `national 
media campaign') in accordance with this section for the purposes of--
            ``(1) preventing drug abuse among young people in the 
        United States;
            ``(2) increasing awareness of adults of the impact of drug 
        abuse on young people; and
            ``(3) encouraging parents and other interested adults to 
        discuss with young people the dangers of illegal drug use.
    ``(b) Use of Funds.--
            ``(1) In general.--Amounts made available to carry out this 
        section for the national media campaign may only be used for 
        the following:
                    ``(A) The purchase of media time and space, 
                including the strategic planning for, and accounting 
                of, such purchases.
                    ``(B) Creative and talent costs, consistent with 
                paragraph (2)(A).
                    ``(C) Advertising production costs.
                    ``(D) Testing and evaluation of advertising.
                    ``(E) Evaluation of the effectiveness of the 
                national media campaign.
                    ``(F) The negotiated fees for the winning bidder on 
                requests for proposals issued either by the Office or 
                its designee to enter into contracts to carry out 
                activities authorized by this section.
                    ``(G) Partnerships with professional and civic 
                groups, community-based organizations, including faith-
                based organizations, and government organizations 
                related to the national media campaign.
                    ``(H) Entertainment industry outreach, interactive 
                outreach, media projects and activities, public 
                information, news media outreach, and corporate 
                sponsorship and participation.
                    ``(I) Operational and management expenses.
            ``(2) Specific requirements.--
                    ``(A) Creative services.--
                            ``(i) In using amounts for creative and 
                        talent costs under paragraph (1)(B), the 
                        Director shall use creative services donated at 
                        no cost to the Government (including creative 
                        services provided by the Partnership for a 
                        Drug-Free America) wherever feasible and may 
                        only procure creative services for 
                        advertising--
                                    ``(I) responding to high-priority 
                                or emergent campaign needs that cannot 
                                timely be obtained at no cost; or
                                    ``(II) intended to reach a 
                                minority, ethnic, or other special 
                                audience that cannot reasonably be 
                                obtained at no cost; or
                                    ``(III) the Director determines 
                                that the Partnership for a Drug-Free 
                                America is unable to provide, pursuant 
                                to subsection (d)(2)(B).
                            ``(ii) No more than $1,500,000 may be 
                        expended under this section each fiscal year on 
                        creative services, except that the Director may 
                        expend up to $2,000,000 in a fiscal year on 
                        creative services to meet urgent needs of the 
                        national media campaign with advance approval 
                        from the Committee on Appropriations of the 
                        House of Representatives and of the Senate upon 
                        a showing of the circumstances causing such 
                        urgent needs of the national media campaign.
                    ``(B) Testing and evaluation of advertising.--In 
                using amounts for testing and evaluation of advertising 
                under paragraph (1)(D), the Director shall test all 
                advertisements prior to use in the national media 
                campaign to ensure that the advertisements are 
                effective and meet industry-accepted standards. The 
                Director may waive this requirement for advertisements 
                using no more than 10 percent of the purchase of 
                advertising time purchased under this section in a 
                fiscal year and no more than 10 percent of the 
                advertising space purchased under this section in a 
                fiscal year, if the advertisements respond to emergent 
                and time-sensitive campaign needs or the advertisements 
                will not be widely utilized in the national media 
                campaign.
                    ``(C) Evaluation of effectiveness of media 
                campaign.--In using amounts for the evaluation of the 
                effectiveness of the national media campaign under 
                paragraph (1)(E), the Director shall--
                            ``(i) designate an independent entity to 
                        evaluate annually the effectiveness of the 
                        national media campaign based on data from--
                                    ``(I) the Monitoring the Future 
                                Study published by the Department of 
                                Health and Human Services;
                                    ``(II) the Attitude Tracking Study 
                                published by the Partnership for a Drug 
                                Free America;
                                    ``(III) the National Household 
                                Survey on Drug Abuse; and
                                    ``(IV) other relevant studies or 
                                publications, as determined by the 
                                Director, including tracking and 
                                evaluation data collected according to 
                                marketing and advertising industry 
                                standards; and
                            ``(ii) ensure that the effectiveness of the 
                        national media campaign is evaluated in a 
                        manner that enables consideration of whether 
                        the national media campaign has contributed to 
                        reduction of illicit drug use among youth and 
                        such other measures of evaluation as the 
                        Director determines are appropriate.
            ``(3) Purchase of advertising time and space.--For each 
        fiscal year, not less than 77 percent of the amounts 
        appropriated under this section shall be used for the purchase 
        of advertising time and space for the national media campaign, 
        subject to the following exceptions:
                    ``(A) In any fiscal year for which less than 
                $125,000,000 is appropriated for the national media 
                campaign, not less than 82 percent of the amounts 
                appropriated under this section shall be used for the 
                purchase of advertising time and space for the national 
                media campaign.
                    ``(B) In any fiscal year for which more than 
                $195,000,000 is appropriated under this section, not 
                less than 72 percent shall be used for advertising 
                production costs and the purchase of advertising time 
                and space for the national media campaign.
    ``(c) Advertising.--In carrying out this section, the Director 
shall ensure that sufficient funds are allocated to meet the stated 
goals of the national media campaign.
    ``(d) Division of Responsibilities and Functions Under the 
Program.--
            ``(1) In general.--The Director, in consultation with the 
        Partnership for a Drug-Free America, shall determine the 
        overall purposes and strategy of the national media campaign.
            ``(2) Responsibilities.--
                    ``(A) Director.--The Director shall be responsible 
                for implementing a focused national media campaign to 
                meet the purposes set forth in subsection (a), and 
                shall approve--
                            ``(i) the strategy of the national media 
                        campaign;
                            ``(ii) all advertising and promotional 
                        material used in the national media campaign; 
                        and
                            ``(iii) the plan for the purchase of 
                        advertising time and space for the national 
                        media campaign.
                    ``(B) The partnership for a drug-free america.--The 
                Director shall request that the Partnership for a Drug-
                Free America--
                            ``(i) develop and recommend strategies to 
                        achieve the goals of the national media 
                        campaign, including addressing national and 
                        local drug threats in specific regions or 
                        States, such as methamphetamine and ecstasy;
                            ``(ii) create all advertising to be used in 
                        the national media campaign, except 
                        advertisements that are--
                                    ``(I) provided by other nonprofit 
                                entities pursuant to subsection (f);
                                    ``(II) intended to respond to high-
                                priority or emergent campaign needs 
                                that cannot timely be obtained at no 
                                cost (not including production costs 
                                and talent reuse payments), provided 
                                that any such advertising material is 
                                reviewed by the Partnership for a Drug-
                                Free America;
                                    ``(III) intended to reach a 
                                minority, ethnic, or other special 
                                audience that cannot be obtained at no 
                                cost (not including production costs 
                                and talent reuse payments), provided 
                                that any such advertising material is 
                                reviewed by the Partnership for a Drug-
                                Free America; or
                                    ``(IV) any other advertisements 
                                that the Director determines that the 
                                Partnership for a Drug-Free America is 
                                unable to provide.
                    ``(C) Media buying contractor.--The Director shall 
                enter into a contract with a media buying contractor to 
                plan and purchase advertising time and space for the 
                national media campaign. The media buying contractor 
                shall not provide any other service or material, or 
                conduct any other function or activity which the 
                Director determines should be provided by the 
                Partnership for a Drug-Free America.
    ``(e) Prohibitions.--None of the amounts made available under 
subsection (b) may be obligated or expended for any of the following:
            ``(1) To supplant current antidrug community-based 
        coalitions.
            ``(2) To supplant pro bono public service time donated by 
        national and local broadcasting networks for other public 
        service campaigns.
            ``(3) For partisan political purposes, or express advocacy 
        in support of or to defeat any clearly identified candidate, 
        clearly identified ballot initiative, or clearly identified 
        legislative or regulatory proposal.
            ``(4) To fund advertising that features any elected 
        officials, persons seeking elected office, cabinet level 
        officials, or other Federal officials employed pursuant to 
        section 213 of Schedule C of title 5, Code of Federal 
        Regulations.
            ``(5) To fund advertising that does not contain a primary 
        message intended to reduce or prevent illicit drug use.
            ``(6) To fund advertising containing a primary message 
        intended to promote support for the media campaign or private 
        sector contributions to the media campaign.
    ``(f) Matching Requirement.--
            ``(1) In general.--Amounts made available under subsection 
        (b) for media time and space shall be matched by an equal 
        amount of non-Federal funds for the national media campaign, or 
        be matched with in-kind contributions of the same value.
            ``(2) No-cost match advertising direct relationship 
        requirement.--The Director shall ensure that at least 70 
        percent of no-cost match advertising provided directly relates 
        to substance abuse prevention consistent with the specific 
        purposes of the national media campaign, except that in any 
        fiscal year in which less than $125,000,000 is appropriated to 
        the national media campaign, the Director shall ensure that at 
        least 85 percent of no-cost match advertising directly relates 
        to substance abuse prevention consistent with the specific 
        purposes of the national media campaign.
            ``(3) No-cost match advertising not directly related.--The 
        Director shall ensure that no-cost match advertising that does 
        not directly relate to substance abuse prevention consistent 
        with the purposes of the national media campaign includes a 
        clear antidrug message. Such message is not required to be the 
        primary message of the match advertising.
    ``(g) Financial and Performance Accountability.--The Director shall 
cause to be performed--
            ``(1) audits and reviews of costs of the national media 
        campaign pursuant to section 304C of the Federal Property and 
        Administrative Services Act of 1949 (41 U.S.C. 254d); and
            ``(2) an audit to determine whether the costs of the 
        national media campaign are allowable under section 306 of such 
        Act (41 U.S.C. 256).
    ``(h) Report to Congress.--The Director shall submit on an annual 
basis a report to Congress that describes--
            ``(1) the strategy of the national media campaign and 
        whether specific objectives of the media campaign were 
        accomplished;
            ``(2) steps taken to ensure that the national media 
        campaign operates in an effective and efficient manner 
        consistent with the overall strategy and focus of the national 
        media campaign;
            ``(3) plans to purchase advertising time and space;
            ``(4) policies and practices implemented to ensure that 
        Federal funds are used responsibly to purchase advertising time 
        and space and eliminate the potential for waste, fraud, and 
        abuse; and
            ``(5) all contracts entered into with a corporation, 
        partnership, or individual working on behalf of the national 
        media campaign.
    ``(i) Local Target Requirement.--The Director shall, to the maximum 
extent feasible, use amounts made available under this section for 
media that focuses on, or includes specific information on, prevention 
or treatment resources for consumers within specific local areas.
    ``(j) Prevention of Marijuana Use.--
            ``(1) Findings.--The Congress finds the following:
                    ``(A) 60 percent of adolescent admissions for drug 
                treatment are based on marijuana use.
                    ``(B) Potency levels of contemporary marijuana, 
                particularly hydroponically grown marijuana, are 
                significantly higher than in the past, rising from 
                under 1 percent of THC in the mid-1970s to as high as 
                30 percent today.
                    ``(C) Contemporary research has demonstrated that 
                youths smoking marijuana early in life may be up to 
                five times more likely to use hard drugs.
                    ``(D) Contemporary research has demonstrated clear 
                detrimental effects in adolescent educational 
                achievement resulting from marijuana use.
                    ``(E) Contemporary research has demonstrated clear 
                detrimental effects in adolescent brain development 
                resulting from marijuana use.
                    ``(F) An estimated 9,000,000 Americans a year drive 
                while under the influence of illegal drugs, including 
                marijuana.
                    ``(G) Marijuana smoke contains 50 to 70 percent 
                more of certain cancer causing chemicals than tobacco 
                smoke.
                    ``(H) Teens who use marijuana are up to four times 
                more likely to have a teen pregnancy than teens who 
                have not.
                    ``(I) Federal law enforcement agencies have 
                identified clear links suggesting that trade in 
                hydroponic marijuana facilitates trade by criminal 
                organizations in hard drugs, including heroin.
                    ``(J) Federal law enforcement agencies have 
                identified possible links between trade in cannabis 
                products and financing for terrorist organizations.
            ``(2) Emphasis on prevention of youth marijuana use.--In 
        conducting advertising and activities otherwise authorized 
        under this section, the Director may emphasize prevention of 
        youth marijuana use.
    ``(k) Authorization of Appropriations.--There is authorized to be 
appropriated to the Office to carry out this section, $195,000,000 for 
each of fiscal years 2007 and 2008 and $210,000,000 for each of fiscal 
years 2009 through 2011.''.
    (b) Repeal of Superseded Provisions.--The Drug-Free Media Campaign 
Act of 1998 (21 U.S.C. 1801 et seq.) is repealed.

SEC. 13. DRUG INTERDICTION.

    (a) In General.--Subsections (a) and (b) of section 711 (21 U.S.C. 
1710) are amended to read as follows:
    ``(a) United States Interdiction Coordinator.--
            ``(1) In general.--The Deputy Director for Supply Reduction 
        in the Office shall serve as the United States Interdiction 
        Coordinator, and shall perform the duties of that position 
        described in paragraph (2) and such other duties as may be 
        determined by the Director with respect to coordination of 
        efforts to interdict illicit drugs from entering the United 
        States.
            ``(2) Responsibilities.--The United States Interdiction 
        Coordinator shall be responsible to the Director for--
                    ``(A) coordinating the interdiction activities of 
                the National Drug Control Program agencies to ensure 
                consistency with the National Drug Control Strategy;
                    ``(B) on behalf of the Director, developing and 
                issuing, on or before March 1 of each year and in 
                accordance with paragraph (3), a National Interdiction 
                Command and Control Plan to ensure the coordination and 
                consistency described in subparagraph (A);
                    ``(C) assessing the sufficiency of assets committed 
                to illicit drug interdiction by the relevant National 
                Drug Control Program agencies; and
                    ``(D) advising the Director on the efforts of each 
                National Drug Control Program agency to implement the 
                National Interdiction Command and Control Plan.
            ``(3) Staff.--The Director shall assign such permanent 
        staff of the Office as he considers appropriate to assist the 
        United States Interdiction Coordinator to carry out the 
        responsibilities described in paragraph (2), and may also, at 
        his discretion, request that appropriate National Drug Control 
        Program agencies detail or assign staff to the Office of Supply 
        Reduction for that purpose.
            ``(4) National interdiction command and control plan.--
                    ``(A) Purposes.--The National Interdiction Command 
                and Control Plan shall--
                            ``(i) set forth the Government's strategy 
                        for drug interdiction;
                            ``(ii) state the specific roles and 
                        responsibilities of the relevant National Drug 
                        Control Program agencies for implementing that 
                        strategy; and
                            ``(iii) identify the specific resources 
                        required to enable the relevant National Drug 
                        Control Program agencies to implement that 
                        strategy.
                    ``(B) Consultation with other agencies.--The United 
                States Interdiction Coordinator shall issue the 
                National Interdiction Command and Control Plan in 
                consultation with the other members of the Interdiction 
                Committee described in subsection (b).
                    ``(C) Limitation.--The National Interdiction 
                Command and Control Plan shall not change existing 
                agency authorities or the laws governing interagency 
                relationships, but may include recommendations about 
                changes to such authorities or laws.
                    ``(D) Report to congress.--On or before March 1 of 
                each year, the United States Interdiction Coordinator 
                shall provide a report on behalf of the Director to the 
                appropriate congressional committees, to the Committee 
                on Armed Services and the Committee on Homeland 
                Security of the House of Representatives, and to the 
                Committee on Homeland Security and Governmental Affairs 
                and the Committee on Armed Services of the Senate, 
                which shall include--
                            ``(i) a copy of that year's National 
                        Interdiction Command and Control Plan;
                            ``(ii) information for the previous 10 
                        years regarding the number and type of seizures 
                        of drugs by each National Drug Control Program 
                        agency conducting drug interdiction activities, 
                        as well as statistical information on the 
                        geographic areas of such seizures; and
                            ``(iii) information for the previous 10 
                        years regarding the number of air and maritime 
                        patrol hours undertaken by each National Drug 
                        Control Program agency conducting drug 
                        interdiction activities, as well as statistical 
                        information on the geographic areas in which 
                        such patrol hours took place.
                    ``(E) Treatment of classified or law enforcement 
                sensitive information.--Any content of the report 
                described in subparagraph (D) that involves information 
                classified under criteria established by an Executive 
                order, or the public disclosure of which, as determined 
                by the United States Interdiction Coordinator or the 
                head of any relevant National Drug Control Program 
                agency, would be detrimental to the law enforcement or 
                national security activities of any Federal, State, or 
                local agency, shall be presented to Congress separately 
                from the rest of the plan.
    ``(b) Interdiction Committee.--
            ``(1) In general.--The Interdiction Committee shall meet 
        to--
                    ``(A) discuss and resolve issues related to the 
                coordination, oversight and integration of 
                international, border, and domestic drug interdiction 
                efforts in support of the National Drug Control 
                Strategy;
                    ``(B) review the annual National Interdiction 
                Command and Control Plan, and provide advice to the 
                Director and the United States Interdiction Coordinator 
                concerning that plan; and
                    ``(C) provide such other advice to the Director 
                concerning drug interdiction strategy and policies as 
                the committee determines is appropriate.
            ``(2) Membership.--The membership of the Interdiction 
        Committee shall consist of--
                    ``(A) the Commissioner of the bureau of Customs and 
                Border Protection at the Department of Homeland 
                Security;
                    ``(B) the Assistant Secretary of the bureau of 
                Immigration and Customs Enforcement at the Department 
                of Homeland Security;
                    ``(C) the Commandant of the United States Coast 
                Guard;
                    ``(D) the Director of the Office of 
                Counternarcotics Enforcement at the Department of 
                Homeland Security;
                    ``(E) the Administrator of the Drug Enforcement 
                Administration;
                    ``(F) the Assistant Secretary of State for 
                International Narcotics and Law Enforcement Affairs;
                    ``(G) the Assistant Secretary of Defense for 
                Special Operations and Low Intensity Conflict;
                    ``(H) the Deputy Director for Supply Reduction of 
                the Office of National Drug Control Policy, acting in 
                his role as the United States Interdiction Coordinator;
                    ``(I) the director of the Crime and Narcotics 
                Center of the Central Intelligence Agency;
                    ``(J) the Deputy Director for State and Local 
                Affairs of the Office of National Drug Control Policy;
                    ``(K) the Chief of the National Guard Bureau's 
                Counterdrug Program; and
                    ``(L) such additional persons as may be determined 
                by the Director.
            ``(3) Chairman.--The Director shall designate one of the 
        members of the Interdiction Committee to serve as chairman.
            ``(4) Meetings.--The members of the Interdiction Committee 
        shall meet, in person and not through any delegate or 
        representative, at least once per calendar year, prior to March 
        1. At the call of either the Director or the current chairman, 
        the Interdiction Committee may hold additional meetings, which 
        shall be attended by the members either in person, or through 
        such delegates or representatives as they may choose.
            ``(5) Report.--Not later than September 30 of each year, 
        the chairman of the Interdiction Committee shall submit a 
        report to the Director and to the appropriate congressional 
        committees describing the results of the meetings and any 
        significant findings of the Committee during the previous 12 
        months. Any content of such a report that involves information 
        classified under criteria established by an Executive order, or 
        whose public disclosure, as determined by the Director, the 
        chairman, or any member, would be detrimental to the law 
        enforcement or national security activities of any Federal, 
        State, or local agency, shall be presented to Congress 
        separately from the rest of the report.''.
    (b) Conforming Amendment to Homeland Security Act of 2002.--Section 
878 of the Homeland Security Act of 2002 (6 U.S.C. 458) is amended--
            (1) in subsection (c), by striking ``Except as provided in 
        subsection (d), the'' and inserting ``The''; and
            (2) by striking subsection (d) and redesignating 
        subsections (e), (f), and (g) as subsections (d), (e), and (f), 
        respectively.

SEC. 14. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL PARTNERSHIPS TO 
              SHUT DOWN ILLICIT DRUG MARKET HOT-SPOTS BY DETERRING DRUG 
              DEALERS OR ALTERING THE DYNAMIC OF DRUG SALES.

    Sections 713 and 714 (21 U.S.C. 1711) are redesignated as sections 
715 and 716, respectively, and after section 712 (21 U.S.C. 1710) 
insert the following new section:

``SEC. 713 AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL PARTNERSHIPS TO 
              SHUT DOWN ILLICIT DRUG MARKET HOT-SPOTS BY DETERRING DRUG 
              DEALERS OR ALTERING THE DYNAMIC OF DRUG SALES.

    ``(a) Awards Required.--The Director shall make competitive awards 
for demonstration programs by eligible partnerships for the purpose of 
shutting down local illicit drug market hot-spots and reducing drug-
related crime through evidence-based, strategic problem-solving 
interventions that deter drug dealers or alter the dynamic of drug 
sales.
    ``(b) Use of Award Amounts.--Award amounts received under this 
section shall be used--
            ``(1) to support the efforts of the agencies, 
        organizations, and researchers included in the eligible 
        partnership;
            ``(2) to develop and field a directed and credible 
        deterrent threat; and
            ``(3) to strengthen rehabilitation efforts through such 
        means as job training, drug treatment, or other services.
    ``(c) Eligible Partnership Defined.--In this section, the term 
`eligible partnership' means a working group whose application to the 
Director--
            ``(1) identifies the roles played, and certifies the 
        involvement of, three or more agencies or organizations, which 
        may include--
                    ``(A) State or local agencies (such as those 
                carrying out police, probation, prosecution, courts, 
                corrections, parole, or treatment functions);
                    ``(B) Federal agencies (such as the Drug 
                Enforcement Agency, the Bureau of Alcohol, Tobacco, 
                Firearms, and Explosives, and United States Attorney 
                offices); and
                    ``(C) community-based organizations;
            ``(2) includes a qualified researcher;
            ``(3) includes a plan for identifying the impact players 
        in, and assessing the nature and dynamic of, the local drug 
        market and its related crime through information gathering and 
        analysis;
            ``(4) includes a plan for developing an evidence-based 
        strategic intervention aimed at quickly and sustainably 
        eradicating the local drug market by deterring drug dealers or 
        altering the dynamic of drug sales; and
            ``(5) includes a plan that describes the methodology and 
        outcome measures proposed for evaluating the impact of that 
        strategic intervention on drug sales, neighborhood disorder, 
        and crime.
    ``(d) Reports to Congress.--
            ``(1) Interim report.--Not later than June 1, 2009, the 
        Director shall submit to Congress a report that identifies the 
        best practices in drug market eradication, including the best 
        practices identified through the activities funded under this 
        section.
            ``(2) Final report.--Not later than June 1, 2010, the 
        Director shall submit to Congress a report on the demonstration 
        programs funded under this section, including on the matters 
        specified in paragraph (1).
    ``(e) Authorization of Appropriations.--There is authorized to be 
appropriated to carry out this section $10,000,000 for each of fiscal 
years 2007 through 2009.''.

SEC. 15. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL PARTNERSHIPS TO 
              COERCE ABSTINENCE IN CHRONIC HARD-DRUG USERS UNDER 
              COMMUNITY SUPERVISION THROUGH THE USE OF DRUG TESTING AND 
              SANCTIONS.

    After section 713, as inserted by section 14 of this Act, insert 
the following new section:

``SEC. 714. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL PARTNERSHIPS TO 
              COERCE ABSTINENCE IN CHRONIC HARD-DRUG USERS UNDER 
              COMMUNITY SUPERVISION THROUGH THE USE OF DRUG TESTING AND 
              SANCTIONS.

    ``(a) Awards Required.--The Director shall make competitive awards 
to fund demonstration programs by eligible partnerships for the purpose 
of reducing the use of illicit drugs by chronic hard-drug users living 
in the community while under the supervision of the criminal justice 
system.
    ``(b) Use of Award Amounts.--Award amounts received under this 
section shall be used--
            ``(1) to support the efforts of the agencies, 
        organizations, and researchers included in the eligible 
        partnership;
            ``(2) to develop and field a drug testing and graduated 
        sanctions program for chronic hard-drug users living in the 
        community under criminal justice supervision; and
            ``(3) to assist individuals described in subsection (a) by 
        strengthening rehabilitation efforts through such means as job 
        training, drug treatment, or other services.
    ``(c) Eligible Partnership Defined.--In this section, the term 
`eligible partnership' means a working group whose application to the 
Director--
            ``(1) identifies the roles played, and certifies the 
        involvement of, two or more agencies or organizations, which 
        may include--
                    ``(A) State or local agencies (such as those 
                carrying out police, probation, prosecution, courts, 
                corrections, parole, or treatment functions);
                    ``(B) Federal agencies (such as the Drug 
                Enforcement Agency, the Bureau of Alcohol, Tobacco, 
                Firearms, and Explosives, and United States Attorney 
                offices); and
                    ``(C) community-based organizations;
            ``(2) includes a qualified researcher;
            ``(3) includes a plan for using judicial or other criminal 
        justice authority to administer drug tests to individuals 
        described in subsection (a) at least twice a week, and to 
        swiftly and certainly impose a known set of graduated sanctions 
        for non-compliance with community-release provisions relating 
        to drug abstinence (whether imposed as a pre-trial, probation, 
        or parole condition or otherwise);
            ``(4) includes a strategy for responding to a range of 
        substance use and abuse problems and a range of criminal 
        histories;
            ``(5) includes a plan for integrating data infrastructure 
        among the agencies and organizations included in the eligible 
        partnership to enable seamless, real-time tracking of 
        individuals described in subsection (a);
            ``(6) includes a plan to monitor and measure the progress 
        toward reducing the percentage of the population of individuals 
        described in subsection (a) who, upon being summoned for a drug 
        test, either fail to show up or who test positive for drugs.
    ``(d) Reports to Congress.--
            ``(1) Interim report.--Not later than June 1, 2009, the 
        Director shall submit to Congress a report that identifies the 
        best practices in reducing the use of illicit drugs by chronic 
        hard-drug users, including the best practices identified 
        through the activities funded under this section.
            ``(2) Final report.--Not later than June 1, 2010, the 
        Director shall submit to Congress a report on the demonstration 
        programs funded under this section, including on the matters 
        specified in paragraph (1).
    ``(e) Authorization of Appropriations.--There is authorized to be 
appropriated to carry out this section $10,000,000 for each of fiscal 
years 2007 through 2009.''.

SEC. 16. AUTHORIZATION OF APPROPRIATIONS.

    Section 716 (21 U.S.C. 1711), as redesignated by section 14 of this 
Act, is amended--
            (1) by striking ``title,'' and inserting ``title, except 
        activities for which amounts are otherwise specifically 
        authorized by this title,''; and
            (2) by striking ``1999 through 2003'' and inserting ``2007 
        through 2011''.

SEC. 17. TECHNICAL AMENDMENTS AND REPEAL.

    (a) Amendment to Public Health Service Act to Replace Obsolete 
References.--Section 464P(c) of the Public Health Service Act (42 
U.S.C. 285o-4(c)) is amended--
            (1) in paragraph (1), by striking ``under section 1002 of 
        the Anti-Drug Abuse Act of 1988 (21 U.S.C. 1501)'' and 
        inserting ``under section 703 of the Office of National Drug 
        Control Policy Reauthorization Act of 1998 (21 U.S.C. 1702)''; 
        and
            (2) in paragraph (2), by striking ``under section 1005 of 
        the Anti-Drug Abuse Act of 1988 (21 U.S.C. 1504)'' and 
        inserting ``under section 706 of the Office of National Drug 
        Control Policy Reauthorization Act of 1998 (21 U.S.C. 1705)''.
    (b) Repeal of Special Forfeiture Fund.--Section 6073 of the Asset 
Forfeiture Amendments Act of 1988 (21 U.S.C. 1509) is repealed.

SEC. 18. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSORSHIP OF ALL 
              FEDERAL ADVERTISING OR OTHER COMMUNICATION MATERIALS.

    Section 712 is amended to read as follows:

``SEC. 712. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSORSHIP OF ALL 
              FEDERAL ADVERTISING OR OTHER COMMUNICATION MATERIALS.

    ``(a) Requirement.--Each advertisement or other communication paid 
for by the Office, either directly or through a contract awarded by the 
Office, shall include a prominent notice informing the target audience 
that the advertisement or other communication is paid for by the 
Office.
    ``(b) Advertisement or Other Communication.--In this section, the 
term `advertisement or other communication' includes--
            ``(1) an advertisement disseminated in any form, including 
        print or by any electronic means; and
            ``(2) a communication by an individual in any form, 
        including speech, print, or by any electronic means.''.

SEC. 19. POLICY RELATING TO SYRINGE EXCHANGE PROGRAMS.

    Section 703(a) (21 U.S.C. 1702(a)) is amended by adding at the end 
the following:
``When developing the national drug control policy, any policy of the 
Director relating to syringe exchange programs for intravenous drug 
users shall be based on the best available medical and scientific 
evidence regarding their effectiveness in promoting individual health 
and preventing the spread of infectious disease, and their impact on 
drug addiction and use. In making any policy relating to syringe 
exchange programs, the Director shall consult with the National 
Institutes of Health and the National Academy of Sciences.''.
                                                 Union Calendar No. 209

109th CONGRESS

  2d Session

                               H. R. 2829

               [Report No. 109-315, Parts I, II, and III]

_______________________________________________________________________

                                 A BILL

     To reauthorize the Office of National Drug Control Policy Act.

_______________________________________________________________________

                             March 3, 2006

  Reported from the Committee on Energy and Commerce with an amendment

                             March 3, 2006

     Reported from the Committee on the Judiciary with an amendment

                             March 3, 2006

  The Permanent Select Committee on Intelligence and the Committee on 
 Education and the Workforce discharged; committed to the Committee of 
  the Whole House on the State of the Union and ordered to be printed
```